1 January, 2016 Curriculum Vitae Steven Kenneth Libutti, M.D., FACS Director, Montefiore-Einstein Center for Cancer Care The Marvin L. Gliedman, M.D. Distinguished Surgeon Professor and Vice Chairman, Department of Surgery Professor, Department of Genetics Albert Einstein College of Medicine Montefiore Medical Center 89 Park Lane 3400 Bainbridge Avenue West Harrison, NY 10604 Medical Arts Pavilion, 4 th Floor (301) 768-8845 Bronx, NY 10467 (718) 920-4231 (718) 798-1883 FAX E-mail: [email protected] Personal Data Born: April 18, 1964, Long Beach, New York. Citizenship: United States of America Married: Mary Frances Douros, November 11, 1990. Children: Christina Marie, DOB August 31, 1992; Melissa Dina, DOB May 11, 1995; Michael Dennis, DOB June 12, 2002. Uniformed Service: US Public Health Service Commissioned Corps Reserve (CAPT, O-6) Extended Active Duty: 1995-2000 Inactive Reserve Corps: 2000-2010 Intermittent Tour Active Duty 2007-2010 Short Tour Active Duty 2006 Short Tour Active Duty 2005 Certifications and Licensure •New York State Medical License #188072-1. •DEA # BL3074527. •Diplomate, American Board of Surgery, # 41027, 1996, recertified, 2004, 2014. •Diplomate, National Board of Medical Examiners, 1991. •Basic Life Support, 2015. •Advanced Cardiac Life Support, 2015. •Advanced Trauma Life Support, 1992.
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
January, 2016
Curriculum Vitae Steven Kenneth Libutti, M.D., FACS Director, Montefiore-Einstein Center for Cancer Care The Marvin L. Gliedman, M.D. Distinguished Surgeon Professor and Vice Chairman, Department of Surgery Professor, Department of Genetics Albert Einstein College of Medicine Montefiore Medical Center 89 Park Lane 3400 Bainbridge Avenue West Harrison, NY 10604 Medical Arts Pavilion, 4th Floor (301) 768-8845 Bronx, NY 10467 (718) 920-4231 (718) 798-1883 FAX E-mail: [email protected] Personal Data Born: April 18, 1964, Long Beach, New York. Citizenship: United States of America Married: Mary Frances Douros, November 11, 1990. Children: Christina Marie, DOB August 31, 1992; Melissa Dina, DOB May 11, 1995; Michael Dennis, DOB June 12, 2002. Uniformed Service: US Public Health Service Commissioned Corps Reserve (CAPT, O-6) Extended Active Duty: 1995-2000 Inactive Reserve Corps: 2000-2010 Intermittent Tour Active Duty 2007-2010 Short Tour Active Duty 2006 Short Tour Active Duty 2005
Certifications and Licensure •New York State Medical License #188072-1. •DEA # BL3074527. •Diplomate, American Board of Surgery, # 41027, 1996, recertified, 2004, 2014. •Diplomate, National Board of Medical Examiners, 1991. •Basic Life Support, 2015. •Advanced Cardiac Life Support, 2015. •Advanced Trauma Life Support, 1992.
2
Academic Appointments •Professor (Tenured), Departments of Surgery and Genetics, Albert Einstein College of Medicine, Bronx, NY 2009-Present. •Vice Chairman, Department of Surgery, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 2009-Present. •The Marvin L. Gliedman, M.D., Distinguished Surgeon, Montefiore Medical Center, Bronx, NY 2009-Present. •Director, Montefiore-Einstein Center for Cancer Care, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 2009-Present. •Associate Director, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 2009-Present. •Director, Endocrine Tumor Program, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 2013-Present. •Professor of Surgery, Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Bethesda, MD 2007-Present. •Head, Tumor Angiogenesis Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2006-2009. •Senior Investigator (Tenured), Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2006-2009. •Investigator (Tenure Track), Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2001-2006. •Staff Clinician, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 2000-2001. •Senior Clinical Investigator (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1999-2000. •Clinical Investigator (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1996-1999. •Assistant Professor of Surgery, Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Bethesda, MD 1996-2007.
3
•Clinical Associate (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1995-1996. •Administrative Chief Resident, Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, NY 1994-95. •Post-Doctoral Residency Fellow, Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, NY 1990-95. Hospital Staff Appointments •Vice Chairman, Department of Surgery, Montefiore Medical Center, Bronx, NY 2009-Present. •Director of Surgery, Jack D. Weiler Hospital, Montefiore Medical Center, Bronx, NY 2009-Present. •Attending Surgeon, Walter Reed Army Medical Center, Washington, DC 2007-2010. •Senior Staff Attending Surgeon, Clinical Center, National Institutes of Health, Bethesda, MD, 1996-2009. •Junior Staff Fellow, Clinical Center, National Institutes of Health, Bethesda, MD, 1995-1996. Post-Graduate Education •Fellow in Surgical Oncology, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1995-96. •Chief Resident in Surgery, Presbyterian Hospital, New York, NY 1994-95. •Resident in Surgery, Presbyterian Hospital, New York, NY 1991-94. •Intern in Surgery, Presbyterian Hospital, New York, NY 1990-91. Medical and Undergraduate Education •College of Physicians & Surgeons of Columbia University, New York, NY Doctor of Medicine, May 1990. •Harvard College, Harvard University, Cambridge, MA
4
Bachelor of Arts in Biology, magna cum laude, June 1986. Honors and Awards: •Federal Laboratory Consortium Award for Excellence in Technology Transfer, 2014. •PheoPara Alliance Science Award, 2012. •Top Doctors New York Metro Area, 2010, 2011, 2012, 2013, 2014, 2015. •America’s Top Doctors, 2010, 2011, 2012, 2013, 2014, 2015. •New York Magazine’s Best Doctors in New York, 2009, 2012, 2013, 2014, 2015. •NCI Director’s Intramural Innovation Award, 2007. •NIH Director’s Award, 2006. •NCI Director’s Gold Star Award, 2006. •Federal Technology Transfer Award, 2003, 2004. •Outstanding Service Award, Surgery Branch, National Cancer Institute, 2000. •Blakemore Prize for Outstanding Body of Research by a Graduating Chief Resident, 1995. •Blakemore Award for Outstanding Research in Surgery, 1991, 1992, 1993, 1994. •First Place 2nd Annual Resident's Research Prize Competition, 1993. •U.S. Congressional Citation for Outstanding Contributions to Medicine, 1993. •Second Place 1st Annual Resident's Research Prize Competition, 1992. •Allen O. Whipple Memorial Prize in Surgery, 1990. •Samuel and Lewis Rover Award in Genetics and Development, 1990. •Sandoz Award for Excellence in Biomedical Research, 1990. •Alpha Omega Alpha Medical Honor Society, elected in 1990. •William Gerety Cup, Intramural Athletics, 1986. •John Harvard Scholarship for Excellence in Academics, 1985. •Harvard College Scholarship for Excellence in Academics, 1983, 1984. Uniformed Service Awards •Commissioned Corps USPHS, Commendation Medal. •Commissioned Corps USPHS, Outstanding Unit Citation. •Commissioned Corps USPHS, Crisis Response Service Award. •Department of Defense, National Defense Service Medal. •Department of Defense, Global War on Terrorism Service Medal. •Commissioned Corps USPHS, Commissioned Corps Training Ribbon. •Commissioned Corps, USPHS, Field Medical Readiness Badge. Editorial Boards Cancer Gene Therapy, Editor-in-Chief Endocrine Related Cancer Journal of Immunotherapy Journal of Surgical Oncology, Section Editor
5
Journal of Translational Medicine, Associate Editor Molecular Cancer, Associate Editor Surgery, Society Editor 2008-2011 Journal and Grant Review Boards (Ad Hoc) Cancer Journal of the National Cancer Institute The British Journal of Surgery The American Journal of Pathology Cancer Research Cancer Research UK Clinical Cancer Research National Institutes of Health SBIR Study Section Sub-Group The Dutch Cancer Society The National Cancer Institute of Canada Microvascular Research Research Interests: Tumor Angiogenesis Antiangiogenic Gene Therapy Regional Perfusion Therapy of Malignant Lesions Isolation and Characterization of Unique Tumor Cytokines Novel Delivery Vehicles for Antineoplastic Agents Molecular and Functional Imaging Society Memberships, Advisory Boards and Committees: • Fellow of the American College of Surgeons • Fellow of the Society of Surgical Oncology • American Association of Endocrine Surgeons, President • International Association of Endocrine Surgeons • Fellow of the American Surgical Association • American College of Surgeons’ Commission on Cancer (NCI and SEER Representative) • Society of University Surgeons • Society of Surgical Oncology, Chair, Technology and Communications Committee • Society of Clinical Surgery • Surgical Biology Club II • Alliance for Clinical Trials in Oncology, Board of Directors • Eastern Cooperative Oncology Group • The Endocrine Society • John Jones Surgical Society, President 2010-2013, Past President 2013-
6
• Association for Academic Surgery • American Association for Cancer Research • American Society of Clinical Oncology • Society for Biological Therapy • Society for Molecular Imaging • The Neuroendocrine Tumor Alliance, Scientific Advisory Board (Charter Member) • Commissioned Officers Association, Board of Directors • Commissioned Officers Foundation, Trustee • Reserve Officers Association • Association of Military Surgeons of the United States • Institutional Review Board, National Cancer Institute, Chairman • National Cancer Institute Representative, NIH Human Subjects Research Advisory Committee • National Cancer Institute Tumor Angiogenesis and Invasion Working Group, Co-Chairman • Trans-Institute Angiogenesis Research Program, Executive Committee, Chair • NIH Assembly of Scientists, elected to Executive Council • NCI CCR Advisory Board Journal Articles 1. Libutti, S. K., Oz, M. C., Forde, K. A., Auteri, J. S., Johnson, J. P., Bass, L. S., and
Treat, M. R. Canine colonic anastomoses reinforced with dye-enhanced fibrinogen and a diode laser. Surg Endosc, 4: 97-99, 1990.
2. Libutti, S. K., Oz, M. C., Chuck, R. S., Auteri, J. S., Treat, M. R., and Nowygrod, R. A preliminary study of dye-enhanced laser photosclerosis. Surgery, 109: 163-168, 1991.
3. Wider, T. M., Libutti, S. K., Greenwald, D. P., Oz, M. C., Yager, J. S., Treat, M. R., and Hugo, N. E. Skin closure with dye-enhanced laser welding and fibrinogen. Plast Reconstr Surg, 88: 1018-1025, 1991.
4. Ashton, R. C., Jr., Libutti, S. K., Oz, M. C., Lontz, J. F., Lemole, G. M., Jr., and Lemole, G. M. The effects of laser-assisted fibrinogen bonding on suture material. J Surg Res, 53: 39-42, 1992.
5. Bass, L. S., Oz, M. C., Libutti, S. K., and Treat, M. R. Alternative wavelengths for sutureless laser microvascular anastomosis: a preliminary study on acute samples. J Clin Laser Med Surg, 10: 207-210, 1992.
6. Oz, M. C., Williams, M. R., Moscarelli, R., Libutti, S. K., Kaynar, M., Fras, C. I., Treat, M. R., and Nowygrod, R. Laser bonding of secondary bronchi with solvent--detergent-treated cryoprecipitate. J Clin Laser Med Surg, 10: 105-107, 1992.
7. Oz, M. C., Libutti, S. K., Ashton, R. C., Lontz, J. F., Lemole, G. M., and Nowygrod, R. Comparison of laser-assisted fibrinogen-bonded and sutured canine arteriovenous anastomoses. Surgery, 112: 76-83, 1992.
8. Bass, L. S., Libutti, S. K., Oz, M. C., Rosen, J., Williams, M. R., Nowygrod, R., and Treat, M. R. Canine choledochotomy closure with diode laser-activated fibrinogen solder. Surgery, 115: 398-401, 1994.
7
9. Kao, J., Houck, K., Fan, Y., Haehnel, I., Libutti, S. K., Kayton, M. L., Grikscheit, T., Chabot, J., Nowygrod, R., Greenberg, S., and et al. Characterization of a novel tumor-derived cytokine. Endothelial- monocyte activating polypeptide II. J Biol Chem, 269: 25106-25119, 1994.
10. Kirsch, A. J., Dean, G. E., Oz, M. C., Libutti, S. K., Treat, M. R., Nowygrod, R., and Hensle, T. W. Preliminary results of laser tissue welding in extravesical reimplantation of the ureters. J Urol, 151: 514-517, 1994.
11. Libutti, S. K. and Starker, P. M. Laparoscopic resection of a nonparasitic liver cyst. Surg Endosc, 8: 1105-1107, 1994.
12. Downey, R. J., Libutti, S. K., Gorenstein, L., and Mercer, S. Airway management during retrieval of the very large aspirated foreign body: a method for the flexible bronchoscope. Anesth Analg, 81: 186-187, 1995.
13. Kirsch, A. J., Chang, D. T., Kayton, M. L., Newhouse, J., Libutti, S. K., Treat, M. R., Connor, J. P., and Hensle, T. W. Sutureless rabbit bladder mucosa patch graft urethroplasty using diode laser and solder. J Urol, 153: 1303-1307, 1995.
14. Kirsch, A. J., Chang, D. T., Kayton, M. L., Libutti, S. K., Connor, J. P., and Hensle, T. W. Effects of diode laser welding with dye-enhanced glue on tensile strength of sutures commonly used in urology. Lasers Surg Med, 18: 167-170, 1996.
15. Kirsch, A. J., Chang, D. T., Kayton, M. L., Libutti, S. K., Treat, M. R., and Hensle, T. W. Laser welding with albumin-based solder: experimental full-tubed skin graft urethroplasty. Lasers Surg Med, 18: 225-230, 1996.
16. Marvin, M. R., Libutti, S. K., Kayton, M., Kao, J., Hayward, J., Grikscheit, T., Fan, Y., Brett, J., Weinberg, A., Nowygrod, R., LoGerfo, P., Feind, C., Hansen, K. S., Schwartz, M., Stern, D., and Chabot, J. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J Surg Res, 63: 248-255, 1996.
17. Bartlett, D. L., Ma, G., Alexander, H. R., Libutti, S. K., and Fraker, D. L. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer, 80: 2084-2090, 1997.
18. Brown, C. K., Bartlett, D. L., Doppman, J. L., Gorden, P., Libutti, S. K., Fraker, D. L., Shawker, T. H., Skarulis, M. C., and Alexander, H. R. Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery, 122: 1189-1193; discussion 1193-1184, 1997.
19. Libutti, S. K., Bartlett, D. L., Jaskowiak, N. T., Skarulis, M., Marx, S. J., Spiegel, A. M., Fraker, D. L., Doppman, J. L., Shawker, T. J., and Alexander, H. R. The role of thyroid resection during reoperation for persistent or recurrent hyperparathyroidism. Surgery, 122: 1183-1187; discussion 1187-1188, 1997.
20. Ma, G. Y., Bartlett, D. L., Reed, E., Figg, W. D., Lush, R. M., Lee, K. B., Libutti, S. K., and Alexander, H. R. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am, 3: 174-179, 1997.
21. Riker, A., Libutti, S. K., and Bartlett, D. L. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol, 6: 157-169, 1997.
22. Alexander, H. R., Bartlett, D. L., Venzon, D. J., Libutti, S. K., Doppman, J. L., Fraker,
8
D. L., Norton, J. A., Gibril, F., and Jensen, R. T. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery, 124: 1160-1166, 1998.
23. Alexander, H. R., Brown, C. K., Bartlett, D. L., Libutti, S. K., Figg, W. D., Raje, S., and Turner, E. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin Cancer Res, 4: 2357-2362, 1998.
24. Alexander, H. R., Jr., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T., and Rosenberg, S. A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol, 16: 1479-1489, 1998.
25. Alexander, H. R., Jr., Bartlett, D. L., and Libutti, S. K. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am, 4: 2-11, 1998.
26. Bartlett, D. L., Buell, J. F., Libutti, S. K., Reed, E., Lee, K. B., Figg, W. D., Venzon, D. J., and Alexander, H. R. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis [published erratum appears in Cancer 1998 Nov 15;83(10):2241]. Cancer, 83: 1251-1261, 1998.
27. Doppman, J. L., Skarulis, M. C., Chang, R., Alexander, H. R., Bartlett, D., Libutti, S. K., Marx, S. J., and Spiegel, A. M. Hypocalcemic stimulation and nonselective venous sampling for localizing parathyroid adenomas: work in progress. Radiology, 208: 145-151, 1998.
28. Libutti, S. K., Choyke, P. L., Bartlett, D. L., Vargas, H., Walther, M., Lubensky, I., Glenn, G., Linehan, W. M., and Alexander, H. R. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery, 124: 1153-1159, 1998.
29. Lubensky, I. A., Pack, S., Ault, D., Vortmeyer, A. O., Libutti, S. K., Choyke, P. L., Walther, M. M., Linehan, W. M., and Zhuang, Z. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol, 153: 223-231, 1998.
30. Park, B. J., Alexander, H. R., Libutti, S. K., Huang, J., Royalty, D., Skarulis, M. C., Jensen, R. T., Gorden, P., Doppman, J. L., Shawker, T. H., Fraker, D. L., Norton, J. A., and Bartlett, D. L. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery, 124: 1056-1061; discussion 1061-1052, 1998.
31. Berger, A. C., Libutti, S. K., Bartlett, D. L., Skarulis, M. G., Marx, S. J., Spiegel, A. M., Doppman, J. L., and Alexander, H. R. Heterogeneous gland size in sporadic multiple gland parathyroid hyperplasia. J Am Coll Surg, 188: 382-389, 1999.
32. Berger, A. C., Buell, J. F., Venzon, D., Baker, A. R., and Libutti, S. K. Management of symptomatic malignant melanoma of the gastrointestinal tract [see comments]. Ann Surg Oncol, 6: 155-160, 1999.
33. Cho, H. K., Lush, R. M., Bartlett, D. L., Alexander, H. R., Wu, P. C., Libutti, S. K., Lee, K. B., Venzon, D. J., Bauer, K. S., Reed, E., and Figg, W. D. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to
9
patients with peritoneal carcinomatosis. J Clin Pharmacol, 39: 394-401, 1999. 34. Desai, S. B. and Libutti, S. K. Tumor angiogenesis and endothelial cell modulatory
factors [see comments]. J Immunother, 22: 186-211, 1999. 35. Feldman, A. L., Sharaf, R. N., Skarulis, M. C., Bartlett, D. L., Libutti, S. K.,
Weinstein, L. S., Marx, S. J., Norton, J. A., Fraker, D. L., and Alexander, H. R. Results of heterotopic parathyroid autotransplantation: a 13-year experience. Surgery, 126: 1042-1048, 1999.
36. Feldman, A. L., Alexander, H. R., Jr., Bartlett, D. L., Fraker, D. L., and Libutti, S. K. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma [see comments]. Ann Surg Oncol, 6: 562-567, 1999.
37. Gnant, M. F., Noll, L. A., Terrill, R. E., Wu, P. C., Berger, A. C., Nguyen, H. Q., Lans, T. E., Flynn, B. M., Libutti, S. K., Bartlett, D. L., and Alexander, H. R., Jr. Isolated hepatic perfusion for lapine liver metastases: impact of hyperthermia on permeability of tumor neovasculature. Surgery, 126: 890-899, 1999.
38. Gnant, M. F., Berger, A. C., Huang, J., Puhlmann, M., Wu, P. C., Merino, M. J., Bartlett, D. L., Alexander, H. R., Jr., and Libutti, S. K. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res, 59: 4668-4674, 1999.
39. Libutti, S. K., Alexander, H. R., Bartlett, D. L., Sampson, M. L., Ruddel, M. E., Skarulis, M., Marx, S. J., Spiegel, A. M., Simmonds, W., and Remaley, A. T. Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. Surgery, 126: 1145-1150; discussion 1150-1141, 1999.
40. Libutti, S. K., Choyke, P., Carrasquillo, J. A., Bacharach, S., and Neumann, R. D. Monitoring responses to antiangiogenic agents using noninvasive imaging tests [In Process Citation]. Cancer J Sci Am, 5: 252-256, 1999.
41. Park, B. J., Alexander, H. R., Libutti, S. K., Wu, P., Royalty, D., Kranda, K. C., and Bartlett, D. L. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol, 6: 582-590, 1999.
42. Walther, M. M., Lyne, J. C., Libutti, S. K., and Linehan, W. M. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology, 53: 496-501, 1999.
43. Wu, P. C., McCart, A., Hewitt, S. M., Turner, E., Libutti, S. K., Bartlett, D. L., and Alexander, H. R. Isolated organ perfusion does not result in systemic microembolization of tumor cells [see comments]. Ann Surg Oncol, 6: 658-663, 1999.
44. Wu, P. C., Alexander, H. R., Huang, J., Hwu, P., Gnant, M., Berger, A. C., Turner, E., Wilson, O., and Libutti, S. K. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)- alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res, 59: 205-212, 1999.
10
45. Zeh, H., Choyke, P. L., Alexander, H. R., Bartlett, D. L., Libutti, S. K., Chang, R., and Summers, R. M. Gadolinium-enhanced 3D MRA prior to isolated hepatic perfusion for metastases. J Comput Assist Tomogr, 23: 664-669, 1999.
46. Alexander, H. R., Libutti, S. K., Bartlett, D. L., Puhlmann, M., Fraker, D. L., and Bachenheimer, L. C. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver [In Process Citation]. Clin Cancer Res, 6: 3062-3070, 2000.
47. Alexander, H. R., Jr., Bartlett, D. L., and Libutti, S. K. Current Status of Isolated Hepatic Perfusion With or Without Tumor Necrosis Factor for the Treatment of Unresectable Cancers Confined to Liver. Oncologist, 5: 416-424, 2000.
48. Bacharach, S. L., Libutti, S. K., and Carrasquillo, J. A. Measuring tumor blood flow with H(2)(15)O: practical considerations. Nucl Med Biol, 27: 671-676, 2000.
49. Berger, A. C., Feldman, A. L., Gnant, M. F., Kruger, E. A., Sim, B. K., Hewitt, S., Figg, W. D., Alexander, H. R., and Libutti, S. K. The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing. J Surg Res, 91: 26-31, 2000.
50. Berger, A. C., Alexander, H. R., Tang, G., Wu, P. S., Hewitt, S. M., Turner, E., Kruger, E., Figg, W. D., Grove, A., Kohn, E., Stern, D., and Libutti, S. K. Endothelial Monocyte Activating Polypeptide II Induces Endothelial Cell Apoptosis and May Inhibit Tumor Angiogenesis. Microvasc Res, 60: 70-80, 2000.
51. Berger, A. C., Alexander, H. R., Wu, P. C., Tang, G., Gnant, M. F., Mixon, A., Turner, E. S., and Libutti, S. K. TUMOUR NECROSIS FACTOR RECEPTOR I (p55) IS UPREGULATED ON ENDOTHELIAL CELLS BY EXPOSURE TO THE TUMOUR-DERIVED CYTOKINE ENDOTHELIAL MONOCYTE- ACTIVATING POLYPEPTIDE II (EMAP-II). Cytokine, 12: 992-1000, 2000.
52. Berger, A. C., Tang, G., Alexander, H. R., and Libutti, S. K. Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis [In Process Citation]. J Immunother, 23: 519-527, 2000.
53. Feingold, D. L., Alexander, H. R., Chen, C. C., Libutti, S. K., Shawker, T. H., Simonds, W. F., Marx, S. J., Skarulis, M. C., Doppman, J. L., Schrump, D. S., and Bartlett, D. L. Ultrasound and sestamibi scan as the only preoperative imaging tests in reoperation for parathyroid adenomas. Surgery, 128: 1103-1110, 2000.
54. Feldman, A. L. and Libutti, S. K. Correspondence re: Q-R. Chen et al., Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res., 59: 3308-3312, 1999 [letter] [In Process Citation]. Cancer Res, 60: 1463-1464, 2000.
55. Feldman, A. L., Restifo, N. P., Alexander, H. R., Bartlett, D. L., Hwu, P., Seth, P., and Libutti, S. K. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice [In Process Citation]. Cancer Res, 60: 1503-1506, 2000.
56. Feldman, A. L. and Libutti, S. K. Progress in antiangiogenic gene therapy of cancer [In Process Citation]. Cancer, 89: 1181-1194, 2000.
11
57. Feldman, A. L., Tamarkin, L., Paciotti, G. F., Simpson, B. W., Linehan, W. M., Yang, J. C., Fogler, W. E., Turner, E. M., Alexander, H. R., Jr., and Libutti, S. K. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.[In Process Citation]. Clin Cancer Res, 6: 4628-4634, 2000.
58. Hirshberg, B., Livi, A., Bartlett, D. L., Libutti, S. K., Alexander, H. R., Doppman, J. L., Skarulis, M. C., and Gorden, P. Forty-eight-hour fast: the diagnostic test for insulinoma [In Process Citation]. J Clin Endocrinol Metab, 85: 3222-3226, 2000.
59. Kershaw, M. H., Westwood, J. A., Zhu, Z., Witte, L., Libutti, S. K., and Hwu, P. Generation of Gene-Modified T Cells Reactive against the Angiogenic Kinase Insert Domain-Containing Receptor (KDR) Found on Tumor Vasculature. Hum Gene Ther, 11: 2445-2452, 2000.
60. Kruger, E. A., Duray, P. H., Tsokos, M. G., Venzon, D. J., Libutti, S. K., Dixon, S. C., Rudek, M. A., Pluda, J., Allegra, C., and Figg, W. D. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun, 268: 183-191, 2000.
61. Kurdziel, K., Bacharach, S., Carrasquillo, J., Huebsch, S., Whatley, M., Sellers, D., Steinberg, S., Libutti, S., Pluda, J., Reed, E., Dahut, W., and Figg, W. 8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide. Clin Positron Imaging, 3: 144, 2000.
62. Libutti, S. K., Barlett, D. L., Fraker, D. L., and Alexander, H. R. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies [In Process Citation]. J Am Coll Surg, 191: 519-530, 2000.
63. Libutti, S. K., Choyke, P. L., Alexander, H. R., Glenn, G., Bartlett, D. L., Zbar, B., Lubensky, I., McKee, S. A., Maher, E. R., Linehan, W. M., and Walther, M. M. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery, 128: 1022-1027;discussion 1027-1028, 2000.
64. Lodge, M. A., Carson, R. E., Carrasquillo, J. A., Whatley, M., Libutti, S. K., and Bacharach, S. L. Parametric images of blood flow in oncology PET studies using [15O]water [In Process Citation]. J Nucl Med, 41: 1784-1792, 2000.
65. McCart, J. A., Puhlmann, M., Lee, J., Hu, Y., Libutti, S. K., Alexander, H. R., and Bartlett, D. L. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression [In Process Citation]. Gene Ther, 7: 1217-1223, 2000.
66. Mohr, V. H., Vortmeyer, A. O., Zhuang, Z., Libutti, S. K., Walther, M. M., Choyke, P. L., Zbar, B., Linehan, W. M., and Lubensky, I. A. Histopathology and Molecular Genetics of Multiple Cysts and Microcystic (Serous) Adenomas of the Pancreas in von Hippel-Lindau Patients. Am J Pathol, 157: 1615-1621, 2000.
67. Puhlmann, M., Brown, C. K., Gnant, M., Huang, J., Libutti, S. K., Alexander, H. R., and Bartlett, D. L. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther, 7: 66-73,
12
2000. 68. Said, B., McCart, J. A., Libutti, S. K., and Choyke, P. L. Ferumoxide-enhanced MRI
in patients with colorectal cancer and rising CEA: surgical correlation in early recurrence. Magn Reson Imaging, 18: 305-309, 2000.
69. Walther, M. C., Shawker, T. H., Libutti, S. K., Lubensky, I., Choyke, P. L., Venzon, D., and Linehan, W. M. A Phase 2 Study of Radio Frequency Interstitial Tissue Ablation of Localized Renal Tumors. J Urol, 163: 1424-1427, 2000.
70. Bartlett, D. L., Libutti, S. K., Figg, W. D., Fraker, D. L., and Alexander, H. R. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery, 129: 176-187., 2001.
71. Berger, A. C., Gibril, F., Venzon, D. J., Doppman, J. L., Norton, J. A., Bartlett, D. L., Libutti, S. K., Jensen, R. T., and Alexander, H. R. Prognostic value of initial fasting serum gastrin levels in patients with zollinger-ellison syndrome. J Clin Oncol, 19: 3051-3057., 2001.
72. Chang, E., Alexander, H. R., Libutti, S. K., Hurst, R., Zhai, S., Figg, W. D., and Bartlett, D. L. Laparoscopic continous hyperthermic peritoneal perfusion. J Am Coll Surg, 193: 225-229., 2001.
73. Crabtree, J. S., Scacheri, P. C., Ward, J. M., Garrett-Beal, L., Emmert-Buck, M. R., Edgemon, K. A., Lorang, D., Libutti, S. K., Chandrasekharappa, S. C., Marx, S. J., Spiegel, A. M., and Collins, F. S. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A, 98: 1118-1123., 2001.
74. Feldman, A. L., Pak, H., Yang, J. C., Alexander, H. R., Jr., and Libutti, S. K. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer, 91: 1525-1529., 2001.
75. Feldman, A. L., Alexander, H. R., Hewitt, S. M., Lorang, D., Thiruvathukal, C. E., Turner, E. M., and Libutti, S. K. Effect of Retroviral Endostatin Gene Transfer on Subcutaneous and Intraperitoneal Growth of Murine Tumors. J Natl Cancer Inst, 93: 1014-1020., 2001.
76. Feldman, A. L., Alexander, H. R., Jr., Bartlett, D. L., Kranda, K. C., Miller, M. S., Costouros, N. G., Choyke, P. L., and Libutti, S. K. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol, 8: 741-745., 2001.
77. Hirshberg, B., Alexander, H. R., Bartlett, D. L., Skarulis, M. C., Libutti, S. K., and Gorden, P. Nesidioblastosis in adults: a clinical enigma(g). J Clin Endocrinol Metab, 86: 2329., 2001.
78. Kayton, M. L. and Libutti, S. K. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature. Curr Opin Investig Drugs, 2: 136-138., 2001.
79. Kivlen, M. H., Bartlett, D. L., Libutti, S. K., Skarulis, M. C., Marx, S. J., Simonds, W. F., Weinstein, L. S., Jensen, R. T., McCart, J. A., Naik, A. M., Kranda, K. C., Brennan, M. F., Norton, J. A., Fraker, D. L., and Alexander, H. R. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery, 130: 991-998.,
13
2001. 80. Lans, T. E., Bartlett, D. L., Libutti, S. K., Gnant, M. F., Liewehr, D. J., Venzon, D. J.,
Turner, E. M., and Alexander, H. R. Role of Tumor Necrosis Factor on Toxicity and Cytokine Production after Isolated Hepatic Perfusion. Clin Cancer Res, 7: 784-790., 2001.
81. Libutti, S. K., Alexander, H. R., Jr., Choyke, P., Bartlett, D. L., Bacharach, S. L., Whatley, M., Jousse, F., Eckelman, W. C., Kranda, K., Neumann, R. D., and Carrasquillo, J. A. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol, 8: 779-786, 2001.
82. McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., Moss, B., and Bartlett, D. L. Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes. Cancer Res, 61: 8751-8757., 2001.
83. Riddell, C., Carson, R. E., Carrasquillo, J. A., Libutti, S. K., Danforth, D. N., Whatley, M., and Bacharach, S. L. Noise reduction in oncology fdg pet images by iterative reconstruction: a quantitative assessment. J Nucl Med, 42: 1316-1323., 2001.
84. Watabe, H., Channing, M. A., Riddell, C., Jousse, F., Libutti, S. K., Carrasquillo, J. A., Bacharach, S. L., and Carson, R. E. Noninvasive estimation of the aorta input function for measurement of tumor blood flow with. IEEE Trans Med Imaging, 20: 164-174., 2001.
85. Zogakis, T. G. and Libutti, S. K. General aspects of anti-angiogenesis and cancer therapy. Expert Opin Biol Ther, 1: 253-275., 2001.
86. Zogakis, T. G., Bartlett, D. L., Libutti, S. K., Liewehr, D. J., Steinberg, S. M., Fraker, D. L., and Alexander, H. R. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol, 8: 771-778, 2001.
87. Albright, S. V., McCart, J. A., Libutti, S. K., Bartlett, D. L., Alexander, H. R., Sampson, M. L., Ruddel, M. E., and Remaley, A. T. Rapid measurement of insulin using the Abbott IMx: application to the management of insulinoma. Ann Clin Biochem, 39: 513-515, 2002.
88. Alexander, H. R., Jr., Libutti, S. K., Bartlett, D. L., Pingpank, J. F., Kranda, K., Helsabeck, C., and Beresnev, T. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer, 95: 730-736, 2002.
89. Calvo, A., Feldman, A. L., Libutti, S. K., and Green, J. E. Adenovirus-mediated Endostatin Delivery Results in Inhibition of Mammary Gland Tumor Growth in C3(1)/SV40 T-Antigen Transgenic Mice. Cancer Res, 62: 3934-3938, 2002.
90. Calvo, A., Yokoyama, Y., Smith, L. E., Ali, I., Shih, S. C., Feldman, A. L., Libutti, S. K., Sundaram, R., and Green, J. E. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer, 101: 224-234, 2002.
14
91. Choyke, P. L., Knopp, M. V., and Libutti, S. K. Special techniques for imaging blood flow to tumors. Cancer J, 8: 109-118, 2002.
92. Costouros, N. G., Diehn, F. E., and Libutti, S. K. Molecular imaging of tumor angiogenesis. J Cell Biochem Suppl, 39: 72-78, 2002.
93. Costouros, N. G., Lorang, D., Zhang, Y., Miller, M. S., Diehn, F. E., Hewitt, S. M., Knopp, M. V., Li, K. C., Choyke, P. L., Alexander, H. R., and Libutti, S. K. Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. Mol Imaging, 1: 301-308, 2002.
94. Diehn, F. E., Costouros, N. G., Miller, M. S., Feldman, A. L., Alexander, H. R., Li, K. C., and Libutti, S. K. Noninvasive fluorescent imaging reliably estimates biomass in vivo. Biotechniques, 33: 1250-1252, 1254-1255, 2002.
95. Elaraj, D. M., Remaley, A. T., Simonds, W. F., Skarulis, M. C., Libutti, S. K., Bartlett, D. L., Venzon, D. J., Marx, S. J., and Alexander, H. R. Utility of rapid intraoperative parathyroid hormone assay to predict severe postoperative hypocalcemia after reoperation for hyperparathyroidism. Surgery, 132: 1028-1034, 2002.
96. Feldman, A. L., Friedl, J., Lans, T. E., Libutti, S. K., Lorang, D., Miller, M. S., Turner, E. M., Hewitt, S. M., and Alexander, H. R. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer, 99: 149-153, 2002.
97. Feldman, A. L., Alexander, H. R., Jr., Yang, J. C., Linehan, W. M., Eyler, R. A., Miller, M. S., Steinberg, S. M., and Libutti, S. K. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer, 95: 1637-1643, 2002.
98. Feldman, A. L., Costouros, N. G., Wang, E., Qian, M., Marincola, F. M., Alexander, H. R., and Libutti, S. K. Advantages of mRNA amplification for microarray analysis. Biotechniques, 33: 906-912, 914, 2002.
99. Friedl, J., Puhlmann, M., Bartlett, D. L., Libutti, S. K., Turner, E. N., Gnant, M. F., and Alexander, H. R. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood, 100: 1334-1339, 2002.
100. Gourgiotis, L., Al-Zubaidi, N., Skarulis, M. C., Papanicolaou, D. A., Libutti, S. K., Alexander Jr, H. R., Merino, M. J., and Sarlis, N. J. Successful Outcome after Surgical Management in Two Cases of the "Painful Variant" of Hashimoto's Thyroiditis. Endocr Pract, 8: 259-265, 2002.
101. Hirshberg, B., Libutti, S. K., Alexander, H. R., Bartlett, D. L., Cochran, C., Livi, A., Chang, R., Shawker, T., Skarulis, M. C., and Gorden, P. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg, 194: 761-764, 2002.
102. Lans, T. E., Ten Hagen, T. L., Van Horssen, R., Wu, P. C., Van Tiel, S. T., Libutti, S. K., Alexander, H. R., and Eggermont, A. M. Improved Antitumor Response to Isolated Limb Perfusion With Tumor Necrosis Factor After Upregulation of Endothelial Monocyte-Activating Polypeptide II in Soft Tissue Sarcoma. Ann Surg Oncol, 9: 812-819, 2002.
103. Libutti, S. K. and Costouros, N. G. Microarray technology and gene expression
15
analysis for the study of angiogenesis. Expert Opin Biol Ther, 2: 545-556, 2002. 104. Marcos, H. B., Libutti, S. K., Alexander, H. R., Lubensky, I. A., Bartlett, D. L.,
Walther, M. M., Linehan, W. M., Glenn, G. M., and Choyke, P. L. Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease: Spectrum of Appearances at CT and MR Imaging with Histopathologic Comparison. Radiology, 225: 751-758, 2002.
105. Marx, S. J., Simonds, W. F., Agarwal, S. K., Burns, A. L., Weinstein, L. S., Cochran, C., Skarulis, M. C., Spiegel, A. M., Libutti, S. K., Alexander, H. R., Jr., Chen, C. C., Chang, R., Chandrasekharappa, S. C., and Collins, F. S. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res, 17 Suppl 2: N37-43, 2002.
106. Pautler, S. E., Richards, C., Libutti, S. K., Linehan, W. M., and Walther, M. M. Intentional Resection of the Diaphragm During Cytoreductive Laparoscopic Radical Nephrectomy. J Urol, 167: 48-50., 2002.
107. Sotiriou, C., Powles, T. J., Dowsett, M., Jazaeri, A. A., Feldman, A. L., Assersohn, L., Gadisetti, C., Libutti, S. K., and Liu, E. T. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res, 4: R3, 2002.
108. Wood, B. J., Ramkaransingh, J. R., Fojo, T., Walther, M. M., and Libutti, S. K. Percutaneous tumor ablation with radiofrequency. Cancer, 94: 443-451, 2002.
109. Yu, J., Steiner, F. A., Muench, J. P., Gourgiotis, L., Skarulis, M. C., Altemus, R. M., Libutti, S. K., Merino, M. J., and Sarlis, N. J. Juxtathyroidal neck soft tissue angiosarcoma presenting as an undifferentiated thyroid carcinoma. Thyroid, 12: 427-432, 2002.
110. Zogakis, T. G., Costouros, N. G., Kruger, E. A., Forbes, S., He, M., Qian, M., Feldman, A. L., Figg, W. D., Alexander, H. R., Liu, E. T., Kohn, E. C., and Libutti, S. K. Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay. Biotechniques, 33: 664-666, 668, 670, 2002.
111. Alexander, H. R., Jr., Libutti, S. K., Pingpank, J. F., Steinberg, S. M., Bartlett, D. L., Helsabeck, C., and Beresneva, T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res, 9: 6343-6349, 2003.
112. Chan, T. J., Libutti, S. K., McCart, J. A., Chen, C., Khan, A., Skarulis, M. K., Weinstein, L. S., Doppman, J. L., Marx, S. J., and Alexander, H. R. Persistent Primary Hyperparathyroidism Caused by Adenomas Identified in Pharyngeal or Adjacent Structures. World J Surg, 2003.
113. Choy, G., O'Connor, S., Diehn, F. E., Costouros, N., Alexander, H. R., Choyke, P., and Libutti, S. K. Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques, 35: 1022-1026, 1028-1030, 2003.
114. Choy, G., Choyke, P., and Libutti, S. K. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging, 2: 303-312, 2003.
115. Elaraj, D. M., Skarulis, M. C., Libutti, S. K., Norton, J. A., Bartlett, D. L., Pingpank, J.
16
F., Gibril, F., Weinstein, L. S., Jensen, R. T., Marx, S. J., and Alexander, H. R. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery, 134: 858-864, 2003.
116. Feldman, A. L., Libutti, S. K., Pingpank, J. F., Bartlett, D. L., Beresnev, T. H., Mavroukakis, S. M., Steinberg, S. M., Liewehr, D. J., Kleiner, D. E., and Alexander, H. R. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol, 21: 4560-4567, 2003.
117. Freedman, N. M., Sundaram, S. K., Kurdziel, K., Carrasquillo, J. A., Whatley, M., Carson, J. M., Sellers, D., Libutti, S. K., Yang, J. C., and Bacharach, S. L. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging, 30: 46-53, 2003.
118. Hwang, J. J., Uchio, E. M., Pavlovich, C. P., Pautler, S. E., Libutti, S. K., Linehan, W. M., and Walther, M. M. Surgical Management of Multi-Organ Visceral Tumors In Patients With Von Hippel-Lindau Disease: A Single Stage Approach. J Urol, 169: 895-898, 2003.
119. Kayton, M. L., Costouros, N. G., Lorang, D., Alexander, H. R., Hewitt, S. M., Cochran, C., Shalev, A., Harlan, D., Skarulis, M. C., Gorden, P., and Libutti, S. K. Peak stimulated insulin secretion is associated with specific changes in gene expression profiles in sporadic insulinomas. Surgery, 134: 982-987, 2003.
120. Keezer, S. M., Ivie, S. E., Krutzsch, H. C., Tandle, A., Libutti, S. K., and Roberts, D. D. Angiogenesis Inhibitors Target the Endothelial Cell Cytoskeleton through Altered Regulation of Heat Shock Protein 27 and Cofilin. Cancer Res, 63: 6405-6412, 2003.
121. Kurdziel, K. A., Figg, W. D., Carrasquillo, J. A., Huebsch, S., Whatley, M., Sellers, D., Libutti, S. K., Pluda, J. M., Dahut, W., Reed, E., and Bacharach, S. L. Using Positron Emission Tomography 2-Deoxy-2-[18F]Fluoro-D-Glucose, 11CO, and 15O-Water for Monitoring Androgen Independent Prostate Cancer. Mol Imaging Biol, 5: 86-93, 2003.
122. Libutti, S. K., Crabtree, J. S., Lorang, D., Burns, A. L., Mazzanti, C., Hewitt, S. M., O'Connor, S., Ward, J. M., Emmert-Buck, M. R., Remaley, A., Miller, M., Turner, E., Alexander, H. R., Arnold, A., Marx, S. J., Collins, F. S., and Spiegel, A. M. Parathyroid Gland-specific Deletion of the Mouse Men1 Gene Results in Parathyroid Neoplasia and Hypercalcemic Hyperparathyroidism. Cancer Res, 63: 8022-8028, 2003.
123. Lonser, R. R., Glenn, G. M., Walther, M., Chew, E. Y., Libutti, S. K., Linehan, W. M., and Oldfield, E. H. von Hippel-Lindau disease. Lancet, 361: 2059-2067, 2003.
124. Neeman, Z., Libutti, S. K., Patti, J. W., and Wood, B. J. Percutaneous radiofrequency ablation of hepatocellular carcinoma in the presence of portal vein thrombosis. Clin Imaging, 27: 417-420, 2003.
125. Oliver, V. K., Patton, A. M., Desai, S., Lorang, D., Libutti, S. K., and Kohn, E. C. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole. J Cell Physiol, 197: 139-148, 2003.
126. Pak, H., Gourgiotis, L., Chang, W. I., Guthrie, L. C., Skarulis, M. C., Reynolds, J. C.,
17
Merino, M. J., Schrump, D. S., Libutti, S. K., Alexander, H. R., Jr., and Sarlis, N. J. Role of metastasectomy in the management of thyroid carcinoma: The NIH experience. J Surg Oncol, 82: 10-18, 2003.
127. Zogakis, T. G., Gibril, F., Libutti, S. K., Norton, J. A., White, D. E., Jensen, R. T., and Alexander, H. R. Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg, 238: 42-48, 2003.
128. Agarwal, S. K., Lee Burns, A., Sukhodolets, K. E., Kennedy, P. A., Obungu, V. H., Hickman, A. B., Mullendore, M. E., Whitten, I., Skarulis, M. C., Simonds, W. F., Mateo, C., Crabtree, J. S., Scacheri, P. C., Ji, Y., Novotny, E. A., Garrett-Beal, L., Ward, J. M., Libutti, S. K., Richard Alexander, H., Cerrato, A., Parisi, M. J., Santa Anna, A. S., Oliver, B., Chandrasekharappa, S. C., Collins, F. S., Spiegel, A. M., and Marx, S. J. Molecular Pathology of the MEN1 Gene. Ann N Y Acad Sci, 1014: 189-198, 2004.
129. Andrea McCart, J., Mehta, N., Scollard, D., Reilly, R. M., Carrasquillo, J. A., Tang, N., Deng, H., Miller, M., Xu, H., Libutti, S. K., Richard Alexander, H., and Bartlett, D. L. Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging after Systemic Delivery Using (111)In-Pentetreotide. Mol Ther, 10: 553-561, 2004.
130. Bourdeau, I., Antonini, S. R., Lacroix, A., Kirschner, L. S., Matyakhina, L., Lorang, D., Libutti, S. K., and Stratakis, C. A. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene, 2004.
131. Feldman, E. D., Wu, P. C., Beresneva, T., Helsabeck, C., Rodriguez, M., Bartlett, D. L., Libutti, S. K., Pingpank, J. F., and Alexander, H. R. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg, 8: 200-207, 2004.
132. Feldman, A. L., Stetler-Stevenson, W. G., Costouros, N. G., Knezevic, V., Baibakov, G., Alexander, H. R., Jr., Lorang, D., Hewitt, S. M., Seo, D. W., Miller, M. S., O'Connor, S., and Libutti, S. K. Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism. Cancer Res, 64: 4481-4486, 2004.
133. Friedman, M., Mikityansky, I., Kam, A., Libutti, S. K., Walther, M. M., Neeman, Z., Locklin, J. K., and Wood, B. J. Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol, 27: 427-434, 2004.
134. Grover, A. C., Libutti, S. K., Pingpank, J. F., Helsabeck, C., Beresnev, T., and Alexander, H. R., Jr. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery, 136: 1176-1182, 2004.
135. Libutti, S. K. Do angiogenesis inhibitors perform a physiologic gatekeeper role in cancer prevention? Cancer J, 10: 12-14, 2004.
136. Martinez, A., Zudaire, E., Portal-Nunez, S., Guedez, L., Libutti, S. K., Stetler-Stevenson, W. G., and Cuttitta, F. Proadrenomedullin NH2-Terminal 20 Peptide Is a Potent Angiogenic Factor, and Its Inhibition Results in Reduction of Tumor Growth.
18
Cancer Res, 64: 6489-6494, 2004. 137. Mazzanti, C., Zeiger, M. A., Costourous, N., Umbricht, C., Westra, W. H., Smith, D.,
Somervell, H., Bevilacqua, G., Alexander, H. R., and Libutti, S. K. Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors. Cancer Res, 64: 2898-2903, 2004.
138. Mazzanti, C. M., Tandle, A., Lorang, D., Costouros, N., Roberts, D., Bevilacqua, G., and Libutti, S. K. Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res, 14: 1585-1593, 2004.
139. McDonald, D. M., Teicher, B. A., Stetler-Stevenson, W., Ng, S. S., Figg, W. D., Folkman, J., Hanahan, D., Auerbach, R., O'Reilly, M., Herbst, R., Cheresh, D., Gordon, M., Eggermont, A., and Libutti, S. K. Report from the Society for Biological Therapy and Vascular Biology Faculty of the NCI Workshop on Angiogenesis Monitoring. J Immunother, 27: 161-175, 2004.
140. Miller, W. J., Kayton, M. L., Patton, A., O'Connor, S., He, M., Vu, H., Baibakov, G., Lorang, D., Knezevic, V., Kohn, E., Alexander, H. R., Stirling, D., Payvandi, F., Muller, G., and Libutti, S. K. A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assayChorioallantoic Membrane (CAM) Assay. J Transl Med, 2: 4, 2004.
141. Minn, A. H., Kayton, M., Lorang, D., Hoffmann, S. C., Harlan, D. M., Libutti, S. K., and Shalev, A. Insulinomas and expression of an insulin splice variant. Lancet, 363: 363-367, 2004.
142. Sundaram, S. K., Freedman, N. M., Carrasquillo, J. A., Carson, J. M., Whatley, M., Libutti, S. K., Sellers, D., and Bacharach, S. L. Simplified Kinetic Analysis of Tumor 18F-FDG Uptake: A Dynamic Approach. J Nucl Med, 45: 1328-1333, 2004.
143. Tandle, Blazer, I. G., and Libutti, S. K. Antiangiogenic gene therapy of cancer: recent developments. J Transl Med, 2: 22, 2004.
144. Alexander, H. R., Jr., Libutti, S. K., Pingpank, J. F., Bartlett, D. L., Helsabeck, C., and Beresneva, T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol, 12: 138-144, 2005.
145. Rosen, J. E., Costouros, N. G., Lorang, D., Burns, A. L., Alexander, H. R., Skarulis, M. C., Cochran, C., Pingpank, J. F., Marx, S. J., Spiegel, A. M., and Libutti, S. K. Gland Size Is Associated With Changes in Gene Expression Profiles in Sporadic Parathyroid Adenomas. Ann Surg Oncol, 2005.
146. Tandle, A. T., Mazzanti, C., Alexander, H. R., Roberts, D. D., and Libutti, S. K. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine, 30: 347-358, 2005.
147. Pingpank, J. F., Libutti, S. K., Chang, R., Wood, B. J., Neeman, Z., Kam, A. W., Figg, W. D., Zhai, S., Beresneva, T., Seidel, G. D., and Alexander, H. R. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J
19
Clin Oncol, 23: 3465-3474, 2005. 148. Libutti, S. K. Understanding the role of gender in the incidence of thyroid cancer.
Cancer J, 11: 104-105, 2005. 149. Hirshberg, B., Cochran, C., Skarulis, M. C., Libutti, S. K., Alexander, H. R., Wood, B.
J., Chang, R., Kleiner, D. E., and Gorden, P. Malignant insulinoma. Cancer, 2005. 150. Agarwal, S. K., Kennedy, P. A., Scacheri, P. C., Novotny, E. A., Hickman, A. B.,
Cerrato, A., Rice, T. S., Moore, J. B., Rao, S., Ji, Y., Mateo, C., Libutti, S. K., Oliver, B., Chandrasekharappa, S. C., Burns, A. L., Collins, F. S., Spiegel, A. M., and Marx, S. J. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res, 37: 369-374, 2005.
151. Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery. 2005 Dec;138(6):1050-6; discussion 1056-7.
152. Grover AC, Skarulis M, Alexander HR, Pingpank JF, Javor ED, Chang R, Shawker T, Gorden P, Cochran C, Libutti SK. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery. 2005 Dec;138(6):1003-8; discussion 1008.
153. Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T, Alexander HR. Limited Survival in Patients With Carcinomatosis From Foregut Malignancies After Cytoreduction and Continuous Hyperthermic Peritoneal Perfusion. J Gastrointest Surg. 2005 Dec 1;9(9):1346-1353.
154. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG. Gene promoter methylation in prostate tumor-associated stromal cells.J Natl Cancer Inst. 2006 Feb 15;98(4):255-61.
155. Kwon M, Libutti SK. Advances in understanding angiogenesis through molecular studies.Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):26-32.
156. Grover AC, Tangrea MA, Woodson KG, Wallis BS, Hanson JA, Chuaqui RF, Gillespie, JW, Erickson HS, Bonner RF, Pohida TJ, Emmert-Buck MR, Libutti SK.
Tumor-Associated Endothelial Cells Display GSTP1 and RARbeta2 Promoter Methylation in Human Prostate Cancer. J Transl Med. 2006 Mar 2;4(1):13.
157. Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, Pacak K, Neumann HP, Paschke R. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer. 2006 May 17;6:131.
158. Libutti SK, Alexander HR Jr. Gastrinoma: sporadic and familial disease. Surg Oncol Clin N Am. 2006 Jul;15(3):479-96.
159. Tang JS, Choy G, Bernardo M, Thomasson D, Libutti SK, Choyke PL. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model. Invest Radiol. 2006 Sep;41(9):691-6.
160. Sudheendra D, Neeman Z, Kam A, Locklin J, Libutti SK, Wood BJ. Intermittent Hepatic Vein Balloon Occlusion During Radiofrequency Ablation in
the Liver. Cardiovasc Intervent Radiol. 2006 Sep 11 161. Wettschureck N, Lee E, Libutti SK, Offermanns S, Robey PG, Spiegel AM.
20
Parathyroid-specific double knockout of Gq- and G11-{alpha} subunits leads to a phenotype resembling germline knockout of the extracellular Ca++-sensing receptor.
Mol Endocrinol. 2006 Sep 20; [Epub ahead of print] 162. Mittendorf EA, Inabnet WB, Libutti SK, McHenry CR, Demeure MJ. Islet Cell Tumors. Curr Probl Surg. 2006 Oct;43(10):685-765. 163. He M, Rosen J, Mangiameli D, Libutti SK. Cancer development and progression. Adv Exp Med Biol. 2007;593:117-33. 164. Rodriguez-Canales J, Hanson J, Tangrea M, Erickson H, Albert P, Wallis B,
Richardson A, Pinto P, Linehan W, Gillespie J, Merino M, Libutti S, Woodson K, Emmert-Buck M, Chuaqui R. Identification of a unique epigenetic sub-microenvironment in prostate cancer. J Pathol. 2007 Feb 2; [Epub ahead of print]
165. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, Poff J, Xie J, Libutti SK, Li KC, Wood BJ. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res. 2007 May 1;13(9):2722-7.
166. Teo BK, Seo Y, Bacharach SL, Carrasquillo JA, Libutti SK, Shukla H, Hasegawa BH, Hawkins RA, Franc BL. Partial-Volume Correction in PET: Validation of an Iterative Postreconstruction Method with Phantom and Patient Data. J Nucl Med. 2007 May;48(5):802-10.
167. Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, Stirling DI, Libutti SK. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med. 2007 Jul 18;5(1):38
168. Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, Libutti SK, Alexander HR, Dedrick RL, Bartlett DL. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2007 Nov 27 [Epub ahead of print].
169. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, LinehanWM, Libutti SK. Clinical, genetic and radiographic analysis of 108 patients with vonHippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms(PNETs). Surgery. 2007 Dec;142(6):814-8.
170. Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK. Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy. Clin Cancer Res. 2008 Jan 1;14(1):270-80.
171. Lodish MB, Powell AC, Abu-Asab M, Cochran C, Lenz P, Libutti SK, Pingpank JF, Tsokos M, Gorden P. Insulinoma and Gastrinoma Syndromes from a Single Intrapancreatic Neuroendocrine Tumor. J Clin Endocrinol Metab. 2008 Feb 5 [Epub ahead of print]
172. Shen H-CJ, Rosen JE, Yang LM, Savage SA, Burns AL, Mateo CM, Agarwal SK, Chandrasekharappa SC, Spiegel AM, Collins FS, Marx SJ, Libutti SK. Parathyroid tumor development involves deregulation of homeobox genes, Endocrine-Related
21
Cancer (2008) 15 267-275. 173. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, Marx SJ,
Gibril F, Jensen RT. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008 Mar;247(3):501-10.
174. Henry LR, Solomon NP, Howard R, Gurevich-Uvena J, Horst LB, Coppit G, Orlikoff R, Libutti SK, Shaha AR, Stojadinovic A. The Functional Impact on Voice of Sternothyroid Muscle Division During Thyroidectomy. Ann Surg Oncol. Ann Surg Oncol. 2008 Jul;15(7):2027-33. Epub 2008 May 6.
175. Hadi M, Bacharach SL, Whatley M, Libutti SK, Straus SE, Rao VK, Wesley R, Carrasquillo JA. Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV. Nucl Med Biol. 2008 May;35(4):441-5. PMID: 18482681 [PubMed - in process]
176. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res. 2008 Jun 1;14(11):3327-37. PMID: 18519760 [PubMed - in process]
177. Powell AC, Stratakis CA, Patronas NJ, Steinberg SM, Batista D, Alexander HR, Pingpank JF, Keil M, Bartlett DL, Libutti SK. Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery. 2008 Jun;143(6):750-8. PMID: 18549891 [PubMed - indexed for MEDLINE]
178. Chung JY, Braunschweig T, Williams R, Guerrero N, Hoffmann KM, Kwon M, Song YK, Libutti SK, Hewitt SM. Factors in Tissue Handling and Processing That Impact RNA Obtained From Formalin-fixed, Paraffin-embedded Tissue. J Histochem Cytochem. 2008 Nov;56(11):1033-42. Epub 2008 Aug 18.
179. Kwon M, Hanna E, Lorang D, He M, Quick JS, Adem A, Stevenson C, Chung JY, Hewitt SM, Zudaire E, Esposito D, Cuttitta F, Libutti SK. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res. 2008 Sep 15;68(18):7332-41.
180. Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, Pérez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W, Lopes JD. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 2008 Oct 15;68(20):8419-28.
181. Hanna E, Quick J, Libutti SK. The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 2009 Jan;15(1):8-17. Epub 2008 Nov 1.
182. Powell AC, Alexander HR, Pingpank JF, Steinberg SM, Skarulis M, Bartlett DL, Agarwal S, Cochran C, Seidel G, Fraker D, Hughes MS, Jensen RT, Marx SJ, Libutti SK. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery. 2008 Dec;144(6):878-83; discussion 883-4.
183. Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha Cancer. 2009 Jan 1;115(1):128-39.
22
184. Guettier JM, Kam A, Chang R, Skarulis MC, Cochran C, Alexander HR, Libutti SK, Pingpank JF, Gorden P. Localization of Insulinomas to Regions of the Pancreas by Intra-Arterial Calcium Stimulation: The NIH Experience. J Clin Endocrinol Metab. 2009 Feb 3. [Epub ahead of print]
185. Shen HC, He M, Powell A, Adem A, Lorang D, Heller C, Grover AC, Ylaya K, Hewitt SM, Marx SJ, Spiegel AM, Libutti SK. Recapitulation of Pancreatic Neuroendocrine Tumors in Human Multiple Endocrine Neoplasia Type I Syndrome via Pdx1-Directed Inactivation of Men1. Cancer Res. 2009 Feb 10. [Epub ahead of print] PMID: 19208834 [PubMed - as supplied by publisher]
186. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS ONE. 2009;4(3):e4972. Epub 2009 Mar 30.
187. Shen HC, Adem A, Ylaya K, Wilson A, He M, Lorang D, Hewitt SM, Pechhold K, Harlan DM, Lubensky IA, Schmidt LS, Linehan WM, Libutti SK. Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS ONE. 2009;4(4):e4897. Epub 2009 Apr 2.
188. Tandle AT, Calvani M, Uranchimeg B, Zahavi D, Melillo G, Libutti SK. Endothelial Monocyte Activating Polypeptide-II Modulates Endothelial Cell Responses by Degrading Hypoxia inducible Factor-1alpha through Interaction with PSMA7, a Component of the Proteasome. Exp Cell Res. 2009 Apr 9. [Epub ahead of print]
189. Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH. Analysis of Factors Associated with Outcome in Patients Undergoing Isolated Hepatic Perfusion for Unresectable Liver Metastases from Colorectal Cancer. Ann Surg Oncol. 2009 May 12. [Epub ahead of print]
190. Holcomb VB, Keck VA, Barrett JC, Hong J, Libutti SK, Núñez NP. Obesity impairs wound healing in ovariectomized female mice. In Vivo. 2009 Jul-Aug;23(4):515-8.
191. Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn. 2009 Jul;9(5):455-66.
192. Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A. Development of a clinical decision model for thyroid nodules. BMC Surg. 2009 Aug 10;9(1):12. [Epub ahead of print]
193. Meir T, Levi R, Lieben L, Libutti S, Carmeliet G, Bouillon R, Silver J, Naveh-Many T. Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the VDR in parathyroid physiology. Am J Physiol Renal Physiol. 2009 Aug 19. [Epub ahead of print]
194. Vu HN, Miller WJ, O'Connor SA, He M, Schafer PH, Payvandi F, Muller GW, Stirling DI, Libutti SK. CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity. J Surg Res. 2009 Feb 24. [Epub ahead of print]
195. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D. MicroRNA dynamics in the stages of tumorigenesis correlate with
23
hallmark capabilities of cancer. Genes Dev. 2009 Sep 15;23(18):2152-65. 196. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry
RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I. Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy. Ann Surg Oncol. 2009 Sep 24. [Epub ahead of print]
197. Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009 Oct;89(5):1105-21.
198. Burton ER, Libutti SK. Targeting TNF-alpha for cancer therapy. J Biol. 2009 Oct 23;8(9):85. [Epub ahead of print]
199. Alexander HR Jr, Fraker DL, Bartlett DL, Libutti SK, Steinberg SM, Soriano P, Beresnev T. Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment Parameters. J Clin Oncol. 2009 Nov 9. [Epub ahead of print]
200. Powell AC, Alexander HR, Chang R, Marx SJ, Skarulis M, Pingpank JF, BartlettDL, Hughes M, Weinstein LS, Simonds WF, Collins MF, Shawker T, Chen CC, Reynolds J, Cochran C, Steinberg SM, Libutti SK. Reoperation for parathyroid adenoma: A contemporary experience. Surgery. 2009 Dec;146(6):1144-55. PubMed:19958942.
201. Shen HC, Libutti SK. The Menin Gene. Cancer Treat Res. 2010;153:273-286. PubMed PMID: 19957230.
202. Powell AC, Libutti SK. Multiple endocrine neoplasia type 1: clinical manifestations and management. Cancer Treat Res. 2010;153:287-302. PMID: 19957231.
203. He M, Mangiameli DP, Kachala S, Hunter K, Gillespie J, Bian X, Shen HC, Libutti SK. Expression Signature Developed from a Complex Series of Mouse Models Accurately Predicts Human Breast Cancer Survival. Clin Cancer Res. 2009 Dec 22. [Epub ahead of print] PubMed PMID: 20028755.
204. Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010 Feb;6(2):229-37. PubMed PMID: 20146582.
205. Powell AC, Paciotti GF, Libutti SK. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol Biol. 2010;624:375-84. PubMed PMID: 20217609.
206. Shen HC, Ylaya K, Pechhold K, Wilson A, Adem A, Hewitt SM, Libutti SK. Multiple Endocrine Neoplasia Type 1 Deletion in Pancreatic {alpha}-Cells Leads to Development of Insulinomas in Mice. Endocrinology. 2010 Jun 16. [Epub ahead of print] PubMed PMID: 20555035.
207. Alsamarai S, Libutti SK, Saif MW. Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP. 2010 Jul 5;11(4):336-40. PubMed PMID: 20601807.
208. Mathur A, Kemp CD, Dutta U, Baid S, Ayala A, Chang RE, Steinberg SM, Papademetriou V, Lange E, Libutti SK, Pingpank JF, Alexander HR, Phan GQ, Hughes M, Linehan WM, Pinto PA, Stratakis CA, Kebebew E. Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg. 2010 Sep;211(3):384-90. Epub 2010 Jul 14. PubMed PMID: 20800196; PubMed Central PMCID: PMC2930893.
24
209. Sreeramoju P, Libutti SK. Strategies for targeting tumors and tumor vasculature for cancer therapy. Adv Genet. 2010;69:135-52. PubMed PMID: 20807606.
210. Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR Jr. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2010 Sep 13. [Epub ahead of print] PubMed PMID: 20839315.
211. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Gannon WE Jr, Walker M, Seidel GD, Yuldasheva N, Tamarkin L. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 Sep 27. [Epub ahead of print] PubMed PMID: 20876255.
212. Libutti SK. Endocrine surgery specialty training: Opportunities for growth. Surgery. 2010 Dec;148(6):1073-4. PubMed PMID: 21134535.
213. Spiegel AM, Libutti SK. Future diagnostic and therapeutic trends in endocrine cancers. Semin Oncol. 2010 Dec;37(6):691-5. Review. PubMed PMID: 21167386.
214. Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, Avital I. Liver Resection and Ablation for Metastatic Adrenocortical Carcinoma. Ann Surg Oncol. 2011 Feb 8. [Epub ahead of print] PubMed PMID: 21301973.
215. Rosen JE, Libutti SK, Lee SL. Thyroid Cancer: Molecular and Modern Advances. J Oncol. 2010;2010:317034. Epub 2011 Feb 7. PubMed PMID: 21331370.
216. Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, Shuttack Y, Libutti SK. A Pilot Feasibility Study of TNFerade™ Biologic with Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer. Oncology. 2011 Mar 25;79(5-6):382-388. [Epub ahead of print] PubMed PMID: 21447969.
217. Spiegel AM, Libutti SK. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors. Nat Rev Clin Oncol. 2011 Mar 29. [Epub ahead of print] PubMed PMID: 21448150.
218. Burton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, Chung JY, Hewitt SM, Huang GS, Goldberg GL, Libutti SK, Kwon M. Down-regulation of filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer. Mol Cancer Res. 2011 Jun 21. [Epub ahead of print] PubMed PMID: 21693594.
219. Webb R, Mathur A, Chang R, Baid S, Nilubol N, Libutti SK, Stratakis CA, Kebebew E. What is the Best Criterion for the Interpretation of Adrenal Vein Sample Results in Patients with Primary Hyperaldosteronism? Ann Surg Oncol. 2011 Nov 3. [Epub ahead of print] PubMed PMID: 22048631.
220. Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery. 2011 Dec;150(6):1122-8. PubMed PMID: 22136831.
25
221. Prasad N, Kowalski J, Tsai HL, Talbot K, Somervell H, Kouniavsky G, Wang Y, Dackiw A, Westra WH, Clark DP, Libutti SK, Umbricht CB, Zeiger MA. Three-Gene Molecular Diagnostic Model for Thyroid Cancer. Thyroid. 2011 Dec 9. [Epub ahead of print] PubMed PMID: 22150595.
222. Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng KK, Eugeni M, Seidel G, Dromi S, Neeman Z, Kolf M, Black CD, Prabhakar R, Libutti SK. Phase I Study of Heat-Deployed Liposomal Doxorubicin during Radiofrequency Ablation for Hepatic Malignancies. J Vasc Interv Radiol. 2012 Feb;23(2):248-255.e7. Epub 2011 Dec 16. PubMed PMID: 22178041; PubMed Central PMCID: PMC3264789.
223. Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2011 Dec 20. doi: 10.1002/jso.23015. [Epub ahead of print] PubMed PMID: 22189845.
224. Arciero CA, Shiue ZS, Gates JD, Peoples GE, Dackiw AP, Tufano RP, Libutti SK, Zeiger MA, Stojadinovic A. Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism. J Cancer. 2012;3:1-6. Epub 2011 Nov 25. PubMed PMID: 22211139; PubMed Central PMCID: PMC3245602.
225. Nilubol N, Weinstein L, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E. Preoperative Localizing Studies for Initial Parathyroidectomy in MEN1 Syndrome: Is There Any Benefit? World J Surg. 2012 Feb 15. [Epub ahead of print] PubMed PMID: 22350475.
226. Weisbrod AB, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK, Marston Linehan W, Nilubol N, Kebebew E. Association of Type O Blood with Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Syndrome. Ann Surg Oncol. 2012 Feb 16. [Epub ahead of print] PubMed PMID: 22350603.
227. Oberstein PE, Remotti H, Saif MW, Libutti SK. Pancreatic neuroendocrine tumors: entering a new era. JOP. 2012 Mar 10;13(2):169-73. PubMed PMID: 22406593.
228. Yavuz S, Simonds WF, Weinstein LS, Collins MT, Kebebew E, Nilubol N, Phan GQ, Libutti SK, Remaley AT, Van Deventer M, Marx SJ. Sleeping Parathyroid Tumor: Rapid Hyperfunction after Removal of the Dominant Tumor. J Clin Endocrinol Metab. 2012 Apr 16. [Epub ahead of print] PubMed PMID: 22508712.
229. Inchauste SM, Lanier BJ, Libutti SK, Phan GQ, Nilubol N, Steinberg SM, Kebebew E, Hughes MS. Rate of Clinically Significant Postoperative Pancreatic Fistula in Pancreatic Neuroendocrine Tumors. World J Surg. 2012 Apr 24. [Epub ahead of print] PubMed PMID: 22526042.
230. Henry L, Helou L, Solomon N, Chang A, Libutti S, Stojadinovic A. Current Practice Patterns Regarding the Conduct of Thyroidectomy and Parathyroidectomy amongst Surgeons - A Survey Study. J Cancer. 2012;3:207-16. Epub 2012 May 12. PubMed PMID: 22606210; PubMed Central PMCID: PMC3354416.
231. Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS. Development and Treatment of Tertiary Hyperparathyroidism in Patients with
26
Pseudohypoparathyroidism Type 1B. J Clin Endocrinol Metab. 2012 Jun 26. [Epub ahead of print] PubMed PMID: 22736772. 232. Weisbrod AB, Nilubol N, Weinstein LS, Simonds WF, Libutti SK, Jensen RT, Marx
SJ, Kebebew E. Association of Type-O Blood with Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. J Clin Endocrinol Metab. 2012 Oct 23. [Epub ahead of print] PubMed PMID: 23093487.
233. Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid H, Libutti SK. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1(MEN1) conditional knockout mouse model. Surgery. 2012 Oct 24. pii:S0039-6060(12)00474-6. doi:10.1016/j.surg.2012.08.021. [Epub ahead of print]PubMed PMID: 23102680.
234. Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ. von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms. Surgery. 2012 Oct 26. doi:pii: S0039-6060(12)00454-0. 10.1016/j.surg.2012.08.010. [Epub ahead of print] PubMed PMID: 23107912.
235. Yuan Z, Syrkin G, Adem A, Geha R, Pastoriza J, Vrikshajanani C, Smith T, Quinn TJ, Alemu G, Cho H, Barrett JC, Arap W, Pasqualini R, Libutti SK. Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity. Cancer Gene Ther. 2012 Nov 16. doi: 10.1038/cgt.2012.83. [Epub ahead of print] PubMed PMID: 23154431.
236. Libutti SK, Inabnet WB 3rd. Force or stratagem? Surgery. 2012 Dec;152(6):975-6. doi: 10.1016/j.surg.2012.08.061. PubMed PMID: 23158171.
237. Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013 Feb;20(2):555-61. doi: 10.1245/s10434-012-2651-5. Epub 2012 Dec 12. PubMed PMID: 23233234.
238. Stevenson R, Libutti SK, Saif MW. Novel agents in gastroenteropancreatic neuroendocrine tumors. JOP. 2013 Mar 10;14(2):152-4. doi: 10.6092/1590-8577/1470. PubMed PMID: 23474560.
239. Stevenson R, Libutti SK, Saif MW. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors. JOP. 2013 Mar 10;14(2):155-7. doi: 10.6092/1590-8577/1472. PubMed PMID: 23474561.
240. Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013 Mar 8. doi:pii: S0039-6060(13)00002-0. 10.1016/j.surg.2013.01.001. [Epub ahead of print] PubMed
27
PMID: 23489943. 241. Nilubol N, Weisbrod AB, Weinstein LS, Simonds WF, Jensen RT, Phan GQ, Hughes
MS, Libutti SK, Marx S, Kebebew E. Utility of Intraoperative Parathyroid Hormone Monitoring in Patients with Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism Undergoing Initial Parathyroidectomy. World J Surg. 2013 May 31. [Epub ahead of print] PubMed PMID: 23722465.
242. Libutti SK. Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours. Nat Rev Endocrinol. 2013 Jun 4. doi: 10.1038/nrendo.2013.109. [Epub ahead of print] PubMed PMID: 23732282.
243. Hong CW, Libutti SK, Wood BJ. Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma. Curr Oncol. 2013 Jun;20(3):e274-7. doi: 10.3747/co.20.1266. PubMed PMID: 23737698; PubMed Central PMCID: PMC3671035.
244. Scholl UI, Goh G, Stölting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Akerström G, Björklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013 Aug 4. doi: 10.1038/ng.2695. [Epub ahead of print] PubMed PMID: 23913001.
245. Gluick T, Yuan Z, Libutti SK, Marx SJ. Mutation in CDKN2C (p18) and CDKN2D (p19) may cause sporadic parathyroid adenoma. Endocr Relat Cancer. 2013 Oct 14. [Epub ahead of print] PubMed PMID: 24127162.
246. Libutti SK. Evolving paradigm for managing small nonfunctional incidentally discovered pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2013 Dec;98(12):4670-2. doi: 10.1210/jc.2013-3696. PubMed PMID: 24311793.
247. Kwon M, Lee SJ, Wang Y, Rybak Y, Luna A, Reddy S, Adem A, Beaty BT, Condeelis JS, Libutti SK. Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis. Int J Cancer. 2013 Dec 10. doi: 10.1002/ijc.28662. [Epub ahead of print] PubMed PMID: 24327474.
248. Kwon M, Lee SJ, Reddy S, Rybak Y, Adem A, Libutti SK. Down-Regulation of Filamin A interacting protein 1-like Is Associated with Promoter Methylation and an Invasive Phenotype in Breast, Colon, Lung and Pancreatic Cancers. PLoS One. 2013 Dec 5;8(12):e82620. doi: 10.1371/journal.pone.0082620. PubMed PMID: 24340050; PubMed Central PMCID: PMC3855469.
249. Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, Liu Y, Venzon D, Turkbey I, Choyke P, Yao J, Libutti SK, Nilubol N, Linehan WM, Kebebew E. Assessment of tumor growth in pancreatic neuroendocrine tumors in von hippel lindau syndrome. J Am Coll Surg. 2014 Feb;218(2):163-9. doi: 10.1016/j.jamcollsurg.2013.10.025. Epub 2013 Nov 12. PubMed PMID: 24440063.
250. Cervera I, Boucai L, Andreopoulou P, Libutti SK, Hughes DT. Referral Patterns for Endocrine Surgical Disease. Endocr Pract. 2014 Jan 21:1-16. [Epub ahead of
28
print] PubMed PMID: 24449658. 251. Libutti SK. New horizons for cancer gene therapy. Cancer Gene Ther. 2014
Jan;21(1):1. doi: 10.1038/cgt.2013.80. PubMed PMID: 24492767. 252. Yuan Z, Opas EE, Vrikshajanani C, Libutti SK, Levine MA. Generation of mice encoding a conditional null allele of Gcm2. Transgenic Res. 2014 Apr 16. [Epub
ahead of print] PubMed PMID: 24736975. 253. Vicente DA, Solomon NP, Avital I, Henry LR, Howard RS, Helou LB, Coppit GL, Shriver CD, Buckenmaier CC, Libutti SK, Shaha AR, Stojadinovic A. Voice Outcomes after Total Thyroidectomy, Partial Thyroidectomy, or Non-Neck Surgery Using a Prospective Multifactorial Assessment. J Am Coll Surg. 2014 Mar 18. pii: S1072-7515(14)00259-2. doi: 10.1016/j.jamcollsurg.2014.03.019. [Epub ahead of
print] PubMed PMID: 24745621. 254. Debelenko LV, Agarwal S, Du Q, Yan W, Erickson HS, Abu-Asab M, Raffeld MA, Libutti SK, Marx SJ, Emmert-Buck MR. Menin Immunoreactivity in Secretory Granules of Human Pancreatic Islet Cells. Appl Immunohistochem Mol Morphol. 2014 Aug 22. [Epub ahead of print] PubMed PMID: 25153502. 255. Kwon M, Libutti SK. Filamin A interacting protein 1-like as a therapeutic target in cancer. Expert Opin Ther Targets. 2014 Sep 9:1-13. [Epub ahead of print] PubMed PMID: 25200207. 256. Cui MH, Branch CA, Cahill SM, Quinn TJ, Adem A, Libutti SK, Yuan Z. In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model. Magn Reson Med. 2014 Nov 13. doi: 10.1002/mrm.25529. [Epub ahead of print] PubMed PMID: 25392979. 257. Gabizon A, Bradbury M, Prabhakar U, Zamboni W, Libutti S, Grodzinski P. Cancer nanomedicines: closing the translational gap. Lancet. 2014 Dec 20;384(9961):2175-6. doi: 10.1016/S0140-6736(14)61457-4. Epub 2014 Dec 19. PubMed PMID: 25625382. 258. Libutti SK. Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs. Cancer Gene Ther. 2015 Mar;22(2):63. doi: 10.1038/cgt.2015.1. PubMed PMID: 25753044. 259. Del Rivero J, Libutti SK. Invited commentary. Radiographics. 2015 Mar-Apr;35(2):516-8. doi: 10.1148/rg.352140286. PubMed PMID: 25763734. 260. Attarian S, Libutti SK, Chuy J. ACTH-Producing Pancreatic Neuroendocrine Tumor Presenting with Severe Hypokalemic Alkalosis: A Case Report. J Gastrointest Cancer. 2015 Jun 16. [Epub ahead of print] PubMed PMID: 26073616. 261. Shah M, Da Silva R, Gravekamp C, Libutti SK, Abraham T, Dadachova E. Targeted radionuclide therapies for pancreatic cancer. Cancer Gene Ther. 2015 Aug;22(8):375- 9. doi: 10.1038/cgt.2015.32. Epub 2015 Jul 31. Review. PubMed PMID:26227823. 262. Hong CW, Chow L, Turkbey EB, Lencioni R, Libutti SK, Wood BJ. Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors. Cardiovasc Intervent Radiol. 2015 Jul 31. [Epub ahead of print] PubMed PMID: 26228246.
29
263. Rosenberg AM, Friedmann P, Del Rivero J, Libutti SK, Laird AM. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery. 2015 Nov 4. pii: S0039-6060(15)00840-5. doi: 10.1016/j.surg.2015.10.013. [Epub ahead of print] PubMed PMID: 26547726. 264. Laird AM, Libutti SK. Minimally Invasive Parathyroidectomy Versus Bilateral Neck Exploration for Primary Hyperparathyroidism. Surg Oncol Clin N Am. 2016 Jan;25(1):103-18. doi: 10.1016/j.soc.2015.08.012. Review. PubMed PMID: 26610777. 265. Libutti SK. Navigating the regulatory road to approval for cancer gene therapies. Cancer Gene Ther. 2015 Dec;22(12):553. doi: 10.1038/cgt.2015.62. PubMed PMID: 26658519. 266. McKimpson WM, Yuan Z, Zheng M, Crabtree JS, Libutti SK, Kitsis RN. The Cell Death Inhibitor ARC Is Induced in a Tissue-Specific Manner by Deletion of the Tumor Suppressor Gene Men1, but Not Required for Tumor Development and Growth. PLoS One. 2015 Dec 28;10(12):e0145792. doi: 10.1371/journal.pone.0145792. eCollection 2015. PubMed PMID: 26709830.
Book Chapters 1. Libutti SK, and Forde KA: Surgical Considerations III: Bowel Anastomosis, In Cohen A., Weaver S. (eds) Cancer of the Colon, Rectum and Anus, McGraw Hill, New York, 1995, Chapter 45, pp. 445-456. 2. Forde KA, and Libutti SK: Lower Gastrointestinal Bleeding, In Raskin JB, Nord HJ (eds) Colonoscopy : Principles & Techniques, Igaku-Shoin Medical Publishers Inc., New York, 1995, Chapter 13, pp. 195-203. 3. Bass LS, Libutti SK, Kayton ML, Nowygrod R, and Treat MR. Soldering Is a Superior Alternative to Fibrin Sealant. In Surgical Adhesives and Sealants: Current Technology and Applications, Sierra DH and Saltz R (ed) Technomic Publishing Co, Inc., Lancaster, PA, 1996, Chapter 5, pp. 41-46. 4. Alexander H.R., Bartlett D.L. and Libutti, S.K., National Cancer Institute Experience with Regional Therapy for Unresectable Primary and Metastatic Cancer of the Liver or Peritoneal Cavity. In Current Clinical Oncology: Regional Chemotherapy: Clinical Research and Practice, Markham, M. (ed) Humana Press, Inc., Totwa, NJ, 1998, Chapter 8, pp. 127-150. 5. Libutti SK, Pluda JM. ANTIANGIOGENESIS: Clinical Applications. In The Biologic Therapy of Cancer, Rosenberg, SA (ed) Lippincott Wiliams & Wilkins, Philadelphia, PA, 2000, Chapter 22, pp. 844 – 861.
30
6. Walther MW, Linehan WM, Libutti SK. Von Hippel-Lindau Disease and Von Recklinghausen’s Disease. In Surgical Endocrinology, Doherty, GM and Skogseid, B (eds) Lippincott Wiliams & Wilkins, Philadelphia, PA, 2000, Chapter 41, pp. 581-591. 7. Alexander HR, Libutti SK. Isolated hepatic perfusion for extensive liver metastases. In Surgery of the Liver and Biliary Tract, Blumgart, LH, and Fong, Y (eds) W.B. Saunders Company LTD, London, England, 2000, Chapter 81b, pp 1607-1615. 8. Libutti SK, Horne MK. Vascular Access and Specialized Techniques of Drug Delivery. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds) Lippincott Wiliams & Wilkins, Philadelphia, PA, 2001, Chapter 29 (Section 2), pp 760-768. 9. Bryan N, Libutti SK. Image Guided Surgery. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds) Lippincott Wiliams & Wilkins, Philadelphia, PA, 2001, Chapter 64, pp 3219-3228. 10. Kohn EC, Libutti SK. Angiogenesis, Vascular Imaging and Therapeutic Approaches in Ovarian Tumors. In Vascular Morphogenesis in the Female Reproductive System. Iruela-Arispe L, Rogers P, Smith S (eds) Springer Verlag, Germany, 2001, Chapter 10, pp 187-205. 11. Libutti SK, Feldman AL. Antiangiogenic Gene Therapy. In Gene Therapy of Cancer, Lattime E, and Gerson S. (eds) Academic Press, New York, 2002, Chapter 26, pp 405-419. 12. Feldman AL, Libutti SK. Antiangiogenesis. In The Cytokine Handbook, Thomson AW, and Lotze MT. (eds) Academic Press, Amsterdam, 2003, Chapter 56, pp 1279-1295. 13. Libutti SK, Saltz LB, Rustgi AK, Tepper JE. Cancer of the Colon. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds) Lippincott Wiliams & Wilkins, Philadelphia, PA, 2005, Chapter 29.8, pp 1061-1109. 14. Libutti SK, Tepper JE, Saltz LB, Rustgi AK. Cancer of the Rectum. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds) Lippincott Wiliams & Wilkins, Philadelphia, PA, 2005, Chapter 29.9, pp 1110-1125. 15. Libutti SK. Cancer. In Greenfield’s Surgery: Scientific Principles and Practice, Mulholland MW, and Lillemoe KD (eds) Lippincott Wiliams & Wilkins, Philadelphia, PA, 2005, Chapter 13, pp 292-317. 16. Libutti SK. Assessing antiangiogenic therapy in preclinical models and clinical trials using noninvasive imaging techniques. In Driving Science: From Bench to Bedside…and Back, AACR 97th Annual Meeting Education Book, Haber DA and Licht J (eds) American Association for Cancer Research, Philadelphia, PA, 2006, Update on Antiangiogenic Therapy in Cancer, pp191-194.
31
17. He M, Rosen J, Mangiameli D, Libutti SK. Cancer Development and Progression. In Microarray Technology and Cancer Gene Profiling, Mocellin S (ed) Landes Bioscience and Springer Science + Business Media, 2007, Chapter 10, pp 117-132. 18. Tandle A, Kwon M, Libutti SK. Genetic Strategies for Targeting Angiogenesis. In Antiangiogenic Cancer Therapy, Davis DW, Herbst RS, Abbruzzese JL (eds) CRC Press Boca Raton, Florida, 2008, Chapter 16, pp 377-413. 19. Libutti SK. Soft Tissue and Skin, Section Editor, Surgical Pitfalls, Evans SRT (ed), Saunders Elsevier, Philadelphia, 2009, pp 489-500. Book Reviews 1. Libutti SK: Review of the textbook Cancer Surgery, Harvey JC, and Beattie EJ, W.B. Saunders Philadelphia, PA, in Oncology 10(7):974, 1996. Visiting Professorships Distinguished Visiting Professor of Surgical Sciences, Department of Surgery, Emory University, Atlanta, GA, April 29-30, 2009. Leon E. Sample Visiting Professor, Yale University School of Medicine, Department of Surgery, New Haven, CT, February 23-24, 2010. Rosen-Rausch Visiting Professor, University of Toronto School of Medicine, Toronto, Ontario, Canada, May 20-21, 2010. George H.A. Clowes Visiting Professor, Harvard Medical School, Beth Israel-Deaconess Medical Center, Department of Surgery, Boston, MA, November 15-17, 2010. Visiting Professor, Harvard Medical School, Brigham and Women’s Hospital, Department of Surgery, Boston, MA, April 29-30, 2014. Robert Ravdin Visiting Professor, University of Pennsylvania Perelman School of Medicine, Department of Surgery, Philadelphia, PA, March 18-19, 2015. Invited Lectures 1996-97 “Surgical Oncology: Surgery & Complications “, Cancer Rehabilitation: From Diagnosis to Return to Function, National Institutes of Health, Bethesda, MD, April, 1996.
32
"Continuous Hyperthermic Peritoneal Perfusion (CHPP) Using Cisplatin and TNF", 2nd International Gastric Cancer Congress, International Gastric Cancer Association., Munich, Germany, April 1997. “Neuroendocrine Tumors of the Pancreas”, Grand Rounds Presentation to the Department of Surgery, Allegheny General Hospital, Allegheny University of the Health Sciences, Pittsburgh, PA, November 4, 1997. “Regional Therapy of Cancer”, Grand Rounds Presentation to the Department of Surgery, College of Physicians & Surgeons of Columbia University, New York, NY, November 13, 1997. 1998-99 “Pancreatic Neuroendocrine Tumors Associated with von Hipple-Lindau”, Clinical Center Grand Rounds, National Institutes of Health, Bethesda, MD, July 15, 1998. “Surgical Oncology”, Resident Teaching Rounds, Department of Surgery, Georgetown University, Washington, DC, August 29, 1998. “The Use of PET and Dynamic MRI to Assess the Effects of Antineoplastic Therapy on Tumor Vasculature and Metabolism”, Conference of the Joint Working Group on Quantitative In Vivo Functional Imaging in Oncology, Arlington, VA, January 7, 1999. “Surgical Endocrinology”, American College of Surgeons Surgical Basic Science Review Course, Uniformed Services University of the Health Sciences, Bethesda, MD, January 9, 1999. “Imaging and Anti-Angiogenic Therapy”, First International Symposium on Anti-Angiogenic Agents, Irving, TX, January 29, 1999. “Advanced Imaging in Surgical Oncology”, Department of Radiology Grand Rounds, Clinical Center, National Institutes of Health, Bethesda, MD, February 26, 1999. “The Effects of Tumor Derived Cytokines on Tumor Associated Vasculature”, NCI/FCRDC Immunology/Cell Biology Seminar Series, Frederick, MD, March 12, 1999. “Assessing the Effects of Antiangiogenic Therapy on Tumor Vasculature and Metabolism Using Functional Imaging”, Biomarkers and Surrogate Endpoints, Advancing Clinical Research and Applications, FDA/NIH Sponsored Symposium, Bethesda, MD, April 16, 1999. “CEA Immunoscintigraphy vs. PET-FDG for the Detection of Colorectal Cancer Recurrence”,
33
29th Annual Spring Meeting, Mid-Eastern Chapter Society of Nuclear Medicine, Herndon Virginia, April 17, 1999. “Pancreatic Neuroendocrine Tumors in VHL”, Annual VHL Family Alliance Patient Provider Conference, Atlanta, GA, June 6, 1999. “Advancing Imaging in Surgical Oncology”, Surgical Grand Rounds, King-Drew Medical Center, Los Angeles, CA, July 23, 1999. “Novel Imaging Methods for Assessing the Activity of Angiogenesis Inhibitors”, DCS Seminars in Clinical and Molecular Oncology, NCI, NIH, Bethesda, MD, September 28, 1999. “Bench to Bedside Rapid Intraoperative Immunoassays: Diagnosis and Treatment of Endocrine Neoplasias”, Clinical Center Grand Rounds, National Institutes of Health, Bethesda, MD, October 6, 1999. “Antiangiogenic Gene Therapy Approaches”, Society for Biological Therapy, Cambridge, MA, October 29, 1999. “Thalidomide in Oncology”, American Society of Health System Pharmacists, Orlando, FL, December 6, 1999. 2000-01 “Endocrine Physiology”, American College of Surgeons Surgical Basic Science Review Course, Uniformed Services University of the Health Sciences, Bethesda, MD, January 8, 2000. “The Use of PET Scan and CEA-Scan for the Localization of Recurrent Colorectal Carcinoma in Patients with Rising Serum CEA Levels”, 7th International Conference on Gastrointestinal Oncology, Arcachon, France, September 28, 2000. “Anti-Angiogenic Gene Therapy Approaches”, NIH Research Festival Plenary Session: Angiogenesis, October 11, 2000. “A Phase II trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients with Recurrent Colorectal Cancer: NCI Update”, 54th Annual Cancer Symposium, Society for Surgical Oncology, Washington, D.C., March 2001. “Tumor Angiogenesis and Anti-Angiogenic Gene Therapy”, 9th Annual Radiation Oncology Symposium at Round Top, Houston, TX, March 30, 2001.
34
“Approaches to the Detection and Management of Colorectal Cancer”, Medicine for the Public Lecture Series, Warren Grant Magnusen Clinical Center, National Institutes of Health, October 9, 2001. “Antiangiogenic Gene Therapy and Endothelial Cell Gene Expression Profiling”, Blaffer Lecture, MD Anderson Cancer Center, Houston, TX, October 25, 2001. 2002-03 “Antiangiogenic Therapy: Is it Effective ?”, American Association for Cancer Research, San Francisco, CA, April 9, 2002. “Antiangiogenic Agents in Clinical Trials and Strategies to Monitor Their Activity”. International Symposium on Angiogenesis and Cancer, Rejavik, Iceland, June 28, 2003. “Studying Tumor Angiogenesis: From Pathways to Patients”, Center for Cancer Research Grand Rounds, October 28th, 2003. 2004-05 “Studying Tumor Angiogenesis: From Pathways to Patients”, Pamela Greenway Kohlmeier Translational Cancer Series, London Regional Cancer Center, London Ontario, Canada, January 22, 2004. “Angiogenesis Inhibitors”, The 4th Jordon Oncology Society Conference and the 1st King Hussein Cancer Center-NCI (USA) Conference, Amman Jordan, April 16, 2004. “Hepatic Radiofrequency Ablation – Present and Future”, The 4th Jordon Oncology Society Conference and the 1st King Hussein Cancer Center-NCI (USA) Conference, Amman Jordan, April 16, 2004. “Advanced Imaging of Cancer”, National Cancer Day, Rome Italy, November 18, 2004. “Targeting the Tumor Vasculature to Treat Cancer”, NIH Director’s Lecture, National Institutes of Health, December 10, 2004. “Regional and Targeted Therapies for Treating Cancer”, Department of Surgery Grand Rounds, St. Lukes-Roosevelt Hospital, January 19, 2005. “The Latest on Gene Tests for Thyroid Cancer”, NCI Designated Comprehensive Cancer Centers Science Writers’ Seminar, Los Angeles, CA, February 23, 2005. “Gene Expression Profiling to Diagnose Benign Versus Malignant Thyroid Nodules”, Thyroid
35
Cancer Survivor’s Workshop, Baltimore, MD, April 16, 2005. “Liver Surgery: Appreciating the New Paradigm”, International Society of Gastrointestinal Oncology, Arlington, VA, July 14, 2005. “Surgical Management of Stage IV Cancer”, Department of Surgery Grand Rounds, University of Massachusetts Hospital Center, September 14, 2005. 2006-07 “Antiangiogenic Approaches to the Management of Melanoma”, Keystone Symposium on Melanoma, Sante Fe, New Mexico, January 22, 2006. “Antiangiogenic Gene Therapy Approaches”, Surgical Neurology Branch Grand Rounds, Bethesda, MD, February 21, 2006. “Regional Approaches to the Management of Stage IV Disease”, Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY, March 14, 2006. “Liver Resection for Colorectal Cancer Metastases”, Grand Rounds, NCI-Navy Medical Oncology, National Naval Medical Center, Bethesda, MD, March 31, 2006. “Imaging Angiogenesis in Preclinical Models and Clinical Trials”, Update on Antiangiogenic Therapy in Cancer, Educational Session, AACR 97th Annual Meeting, Washington, DC, April 1, 2006. “Regional Therapy for Advanced Malignancies”, Surgeons’ Travel Club, National Institutes of Health, Bethesda, MD, April 29, 2006. “Targeting the Tumor Microenvironment for Cancer Therapy”, CCR Grand Rounds, National Cancer Institute, Bethesda, MD, October 3, 2006. “Molecular Markers in Thyroid Tumors”, American College of Surgeons 92nd Annual Clinical Congress, Chicago, IL, October 10, 2006. “Targeted Delivery of Anti-Vascular Agents to Tumors”, AACR Innovations in Prostate Cancer Research, San Francisco, CA, December 9, 2006. “Targeting the Tumor Vasculature to Treat Cancer”, Department of Surgery Grand Rounds, Washington Hospital Center, Washington, DC, April 10, 2007. “Tumor Targeted Therapies”, Cancer Coalition Grand Rounds, Frederick Memorial Hospital,
36
Frederick, MD, April 20, 2007. “Role of the Surgeon in Managing Stage IV Disease”, Surgery Grand Rounds, Western Pennsylvania Hospital, Pittsburgh, PA, May 9, 2007. “Therapeutic Paradigms for Cancer”, Physician Category Day, Scientific and Training Symposium, Commissioned Officers’ Association Annual Meeting, Cincinnati, OH, June 5, 2007. “Update on the Management of Pancreas Lesions in vHL”, VHL Family Alliance Annual Meeting, Boston, MA, June 24, 2007. “Changing Paradigms for the Treatment of Cancer”, Department of Surgery Grand Rounds, Columbia-Presbyterian Hospital, New York, NY, June 28, 2007. 2008-09 “Surgery for Metastasis and Local Recurrence”, 2nd Annual International Adrenal Cancer Symposium: Clinical and Basic Science, University of Michigan Medical School, Ann Arbor, MI, March 14, 2008. “Regional and Targeted Therapies for the Treatment of Cancer”, Department of Surgery Grand Rounds, Montefiore Hospital and the Albert Einstein College of Medicine, Bronx, NY, March 24, 2008. “Novel Approaches for the Treatment of Cancer”, Mark Kavolius Lecture in Surgical Oncology, 30th Annual Gary P. Wratten Symposium, Uniformed Services University of the Health Sciences, Bethesda, MD, May 1, 2008. “Mouse Models for Pancreatic Neuroendocrine Tumors in MEN1”, MEN1 Annual Scientific Symposium, Delphi, Greece, September 26, 2008. “Targeting the Vasculature to Treat Cancer”, Surgical Biology Club II Symposium, San Francisco, CA, October 12, 2008. “Re-operative Parathyroidectomy”, Endocrine Surgery Video Session, American College of Surgeons, San Francisco, CA, October 14, 2008. “Treatment of Primary Rectal Cancer Using TNFeradeTM, Chemoradiation and Surgery”, VII International Symposium Sphincter Saving Surgery for Rectal Cancer, Milan, Italy, November 18, 2008. “Use of Targeted Therapy to Treat Cancer”, Department of Surgery Grand Rounds, University
37
of Louisville, Louisville, KY, January 16, 2009. “Evolution of Regional Therapy”, Visiting Professor Grand Rounds, Department of Surgery, Scott and White Hospital, Texas A&M University, Temple, TX, February 19, 2009. “Translational Science”, Howard Hughes Medical Institute, National Institutes of Health, Bethesda, MD, February 23, 2009. “The Use of Colloid Gold Nanoparticles to Treat Cancer”, Society of Surgical Oncology Annual Meeting, Phoenix, AZ, March 5, 2009. “The Evolution of Regional Therapy”, Distinguished Visiting Professor of Surgical Sciences, Department of Surgery, Emory University, Atlanta, GA, April 30, 2009. “How Do I Choose the Best Surgeon?”, PheoPara Alliance, Parsippany, NJ, October 2, 2009. “Pheochromocytoma”, Controversies and Problems in Surgery, New York, NY, December 12, 2009. “Functional Neuroendocrine Tumors”, Controversies and Problems in Surgery, New York, NY, December 12, 2009. 2010-2011 “Targeted Cancer Therapy: Evolving Approaches”, 52nd Annual Leon E. Sample Memorial Lecture, Yale University School of Medicine Department of Surgery, New Haven, CT, February 24, 2010. “Neuroendocrine Tumors: Management, Monitoring and Models”, Rosen-Rausch Lecture, University of Toronto School of Medicine, Toronto, Ontario, Canada, May 21, 2010. “Overcoming the Inefficiencies of Oncology Drug Development”, Oncology Clinical Trial Designs to Achieve Proof of Concept, NextLevel Pharma, Brussels, Belgium, September 29, 2010. “New Strategies for the Targeted Therapy of Cancer”, Grand Rounds, Beth Israel-Deaconess Medical Center, Department of Surgery, Boston, MA, November 17, 2010. “Gold Nanoparticles for Human Cancer Therapy”, 4th Dutch Interdisciplinary Congress of the NVCO, NVMO and NVRO, Oncology Tailored Therapy, Arnhem, Netherlands, February 10, 2011. “Gold Nanoparticles for Human Cancer Therapy”, Practical Nanotechnologies, AACR 102nd
38
Annual Meeting, Orlando, Florida, April 2, 2011. “Clinical Applications of Nanotechnology”, Association of Health Care Journalists, Philadelphia, Pennsylvania, April 15, 2011. “New Strategies for Targeted Cancer Therapy”, New York State Chapter of the American College of Surgeons, Annual Meeting, Bronx, New York, May 1, 2011. “Evolution of regional therapy for metastatic neuroendocrine tumors of the liver – from IHP to PHP”, 80th Annual Scientific Congress, Royal Australasian College of Surgeons, Adelaide, Australia, May 5, 2011. “Chemo-saturation-PHP with Melphalan for melanoma metastatic to the liver: preliminary results of a phase III study”, 80th Annual Scientific Congress, Royal Australasian College of Surgeons, Adelaide, Australia, May 5, 2011. “New Strategies for the Treatment of Neuroendocrine Tumors”, Department of Surgery Grand Rounds, College of Physicians & Surgeons, Columbia University, New York-Presbyterian Hospital, New York, NY, May 18, 2011. “Gold Nanoparticle Therapy for Malignancy”, Gastrointestinal Cancer, Therapeutic Endoscopy and Abdominal Transplant Symposium 2011: Innovative Technology in Medical and Surgical Decision-Making, Tulane University, New Orleans, Louisiana, June 11, 2011. “New Approaches to the Study and Treatment of Neuroendocrine Tumors”, Department of Medicine, Division of Medical Oncology Grand Rounds, College of Physicians & Surgeons, Columbia University, New York-Presbyterian Hospital, New York, NY, October, 2011. “Evolution of a New Treatment Modality for Metastatic Liver Cancer from Major Surgery to Percutaneous Intervention”, AIM Symposium 2011, New York, New York, November 17, 2011. “New Approaches to the Study and Treatment of Neuroendocrine Tumors”, Department of Surgery Grand Rounds, University of Tennessee College of Medicine, Chattanooga, Tennessee, November 30, 2011. 2012-2013 “Evolving Approaches for the Treatment of Neuroendocrine Tumors”, Department of Surgery Grand Rounds, Mount Sinai Medical Center, New York, New York, January 2012. “Pancreatic Neuroendocrine Tumors: Entering a New Era”, Cancer Center Grand Rounds, University of Massachusetts, Worcester, Massachusetts, April 3, 2012.
39
“Nanomedicines for Cancer Therapy”, 1st International Symposium on Nanomedicine in Drug Delivery and Cancer Diagnosis, University of Delaware, Newark, Delaware, August 16, 2012. “Liver Metastases from Neuroendocrine Tumors: Chemoperfusion”, American College of Surgeons Annual Clinical Congress, Chicago, Illinois, October 2, 2012. “Nanoparticle Therapeutics”, National Cancer Institute Centers for Cancer Nanotechnology Excellence PI Retreat, Methodist Research Institute, Houston, Texas, November 14, 2012. “Update on Diagnosing and Treating Pancreatic Neuroendocrine Tumors (pNETs)”, vHL Family Alliance Annual Meeting, Dana Farber Cancer Institute, Harvard University, Boston, Massachusetts, November 17, 2012. “Multiple Endocrine Neoplasia Defined”, 1st Annual New York Endocrine Surgery Course, Mount Sinai Medical Center, New York, New York, November 30, 2012. “Functioning Pancreatic Neuroendocrine Tumors”, 1st Annual New York Endocrine Surgery Course, Mount Sinai Medical Center, New York, New York, December 1, 2012. “New Strategies for the Treatment of Neuroendocrine Tumors”, Cancer Center Grand Rounds, Cancer Institute of New Jersey, New Brunswick, New Jersey, December 5, 2012. “Pancreatic Neuroendocrine Tumors in vHL: Challenges and Opportunities”, Cancer Center Grand Rounds, University of Calgary, Calgary, Alberta, Canada, February 7, 2013. “Developing New Treatments for Neuroendocrine Tumors Using Animal Models”, Department of Surgery Grand Rounds, University of Calgary, Calgary, Alberta, Canada, February 8, 2013. “The Benefits of Multidisciplinary Teams Treating NETs”, Carcinoid Cancer Awareness Network, New York, NY, April 6, 2013. “Gastroenteropancreatic Neuroendocrine Tumors”, Department of Surgery Grand Rounds, Montefiore Medical Center, Bronx, NY, May 6, 2013. “Targeted Cancer Therapy”, Cancer Care for Scientists and Engineers, Boston University, Boston, MA, May 14, 2013. “New Approaches for the Treatment of Neuroendocrine Tumors”, Endocrine Grand Rounds, University of Wisconsin School of Medicine, Madison, WI, May 16, 2013. “Novel Approaches for the Study and Management of Neuroendocrine Tumors”, Grand
40
Rounds, University of Chicago School of Medicine, Chicago, IL, December 4, 2013. “Management of NET Metastases and Unresectable NETs”, Masters Course in Endocrine Surgery, Mount Sinai Medical Center, New York, NY, December 5, 2013. “Rare Familial Conditions”, Masters Course in Endocrine Surgery, Mount Sinai Medical Center, New York, NY, December 5, 2013. “Hyperaldosteronism”, Masters Course in Endocrine Surgery, Mount Sinai Medical Center, New York, NY, December 6, 2013. “Evolving Approaches to the Treatment of Neuroendocrine Tumors”, Grand Rounds, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, December 12, 2013. 2014-2015 “Neuroendocrine Tumors: From Bedside to Bench and Back”, Department of Surgical Oncology Grand Rounds, MD Anderson Cancer Center, Houston, TX, January 15, 2014. “Evidence-Based Adjuvant Treatment Options for Gastropancreatic NETs”, 67th Annual Society of Surgical Oncology Cancer Symposium, Phoenix, AZ, March 13, 2014. “New Strategies for the Diagnosis and Treatment of Neuroendocrine Tumors”, Roswell Park Cancer Institute, Buffalo, NY, January 26, 2015. “Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)”, ENETs, Barcelona, Spain, March 12, 2015. “New Approaches to the Study and Treatment of Neuroendocrine Tumors”, Department of Pathology Grand Rounds, Weill Cornell Medical College, New York, NY, May 1, 2015. “New Strategies for the Study and Treatment of Neuroendocrine Tumors”, Department of Surgery Grand Rounds, MedStar Washington Hospital Center, Washington, DC, September 22, 2015. “New Developments in Targeted Gold Nanomedicines”, American Society for Nanomedicine, Washington, DC, October 16, 2015. “Evolving Approaches to the Management of Neuroendocrine Tumors”, World Congress for the Advancement of Surgery, Tel Aviv, Israel, October 20, 2015. “Advances in the Treatment and Understanding of Neuroendocrine Tumors”,
41
Lower-New York AACE Annual Meeting, New York, NY, October 31, 2015. “Neuroendocrine Tumors: Medical And Surgical Management”, AIM Symposium, New York, NY, November 10, 2015. “Outcomes and Quality Improvement in PNET and GI NET Surgery”, 3rd NY Masters Course in Endocrinology and Endocrine Surgery, New York, NY, December 11, 2015. Current Clinical Trials Neuroendocrine Tissue Banking and Genomics (09-06-173) Libutti (PI) RAD001t2302 (11-06-318) Libutti (PI) - A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin -RADIANT-4 (Sponsor – Novartis) Alliance A021202 (2013-2453) Libutti (PI) Prospective Randomized Phase II Trial of Pazopanib versus Placebo in Patients with Progressive Carcinoid Tumors (Sponsor – NCI) ECOG E2211 (2013-2262) Libutti (PI) A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (Sponsor – NCI) ECOG E2212 (2014-3023) Libutti (PI and ECOG Study Chair) A randomized, double-blinded, placebo-controlled Phase II study of adjuvant everolimus following the resection of metastatic pancreatic neuroendocrine tumors to the liver (Sponsor – NCI) Current Research Support • R01CA170911 Libutti (PI) 09/01/12-06/30/17 “Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis” NCI Provocative Questions RFA Total Support: $1,732,625 • DOD W81XWH-15-1-0369 Libutti (PI) 09/01/15-08/31/18 “FILIP1L inhibits ovarian cancer metastasis through inhibition of WNT signaling” Total Support: $757,477 • U54CA151668 8847 Libutti (PI) 09/01/10-08/31/16 “Multifunctional Nanoassemblies for Ligand-Directed Imaging and Therapy of Endocrine Tumors of the Pancreas” Total Support: $710,370
42
• T32CA200561 Libutti (PI) 12/01/15-11/30/20 “Training of Surgeons for Studies of the Tumor Microenvironment” Total Requested Support: $1,352,720 • R01DK079970 Levine (Libutti Sub-K) 09/22/12-06/30/16 “The role of GCM2 in parathyroid gland homeostasis” Total Support: $235,524 P50CA174521 Libutti (PI) 09/01/15-08/31/16 Pilot Grant from University of Iowa NET SPORE Characterization of new B7 immune-checkpoints in the tumor microenvironment of human carcinoid and pancreatic neuroendocrine tumors. • Alliance Libutti (Site PI) American College of Surgeons Oncology Group, cooperative clinical trials in cancer. Sponsored by the National Cancer Institute. Completed Research Support • Linda and Earle Altman Libutti (PI) 06/01/10-06/30/15 “Studies of the tumor microenvironment and tumor associated vasculature” Unrestricted research gift. Total Support: $1,250,000 • 2012 Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic
Neuroendocrine Tumor Research Pasqualini (Libutti Co-PI) 07/01/12-06/30/14 “Octreotide-targeted treatment of neuroendocrine tumors of the pancreas” Total Support: $250,000 • Speracura, LLC Libutti (PI) 09/20/10-09/19/13 Endocrine/Neuroendocrine Tumor Program Total Support: $330,000 •Pheo/Para Alliance Libutti (PI) 07/01/11-07/01/13 “Genomic profiling of pheochromocytomas” Total Support: $75,000 • AECC - Pilot Project Grant Libutti (PI) 03/01/11-02/28/12
43
“To discover novel pathways involved in the formation of endocrine tumors using high throughput genomic approaches” Total Support: $15,000 •AECOM – Dean’s Pilot Grant Libutti (PI) 06/01/11-05/31/12 “Understanding the formation of endocrine tumors using high throughput global RNA massively-parallel sequencing” Total Support: $15,000
• NCI - Z01 SC 010368 Libutti (PI) 10/01/01-06/30/09 “Targeting the Tumor Vasculature to Treat Cancer” NCI Tenured Intramural Scientist: novel approaches to the targeted therapy of cancer. Total Support: $7,200,000 Patents 1. Bass LS, Libutti SK, Eaton AM, Tissue bonding and sealing composition and methods of using the same, U. S. Patents 5,209,776 and 5,292,362. 2. Stern D, Clauss M, Kao J, Kayton ML, Libutti SK, Antibody which specifically binds to endothelial monocyte activating polypeptide II, U.S. Patent 5,641,867. 3. Stern D, Clauss M, Kao J, Kayton ML, Libutti SK, Endothelial monocyte activating polypeptide II: a mediator which activates host response, U.S. Patents 6,228,837 and 6,734,168. 4. Libutti SK, Zeiger MA, Mazzanti C, Umbricht C, Diagnostic tool for diagnosing benign versus malignant thyroid lesions, U.S. Patent 7,901,881. 5. Libutti SK, Kwon M, Tandle A, FILIPIL compositions and methods for treating cancer, U.S. Patent 8,501,912. 6. Libutti SK, He M, Molecular-based method of cancer diagnosis and prognosis, U.S. Patents 8,715,928, and 9,181,589. 7. Libutti SK, Yuan Z, Combination therapy using a targeted inducer of apoptosis combined with an inhibitor of inhibitor of apoptotic proteins (IAP’s) for the treatment of cancer, U.S. Patent Pending, U.S. Serial No. 61/537,250.
Related Documents
